<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>NuLegal Blog</title><description>Legal resources and litigation updates across the mass torts NuLegal reviews, covering prescription drugs, implanted devices, medical procedures, and online platforms.</description><link>https://nulegal.com/</link><item><title>GLP-1 Vision Claims: Why the Timing of a NAION Warning Matters</title><link>https://nulegal.com/blog/glp-1-vision-claims-why-the-timing-of-a-naion-warning-matters/</link><guid isPermaLink="true">https://nulegal.com/blog/glp-1-vision-claims-why-the-timing-of-a-naion-warning-matters/</guid><description>JD Supra reports that an FDA warning about NAION affects who may qualify for a GLP-1 vision loss claim. Learn why the date you started the drug and the date your vision changed both matter.</description><pubDate>Sat, 21 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Recent legal coverage, including a JD Supra analysis, reports that the FDA has addressed non-arteritic anterior ischemic optic neuropathy (NAION) in connection with GLP-1 drugs. The headline said the warning &amp;quot;affects who may qualify&amp;quot; for a vision loss claim.&lt;/p&gt;
&lt;p&gt;That framing is correct, and anyone who lost vision after taking Ozempic, Wegovy, Rybelsus or Mounjaro should understand why. A failure-to-warn case turns on what the drugmaker told doctors, and when it told them. A label change splits patients into those who started a GLP-1 drug before any NAION warning existed and those who started after.&lt;/p&gt;
&lt;p&gt;Check the exact wording and date of any label change against the FDA record, not a news summary. The timing questions below apply whatever those details turn out to be.&lt;/p&gt;
&lt;p&gt;NAION is a loss of blood flow to the front of the optic nerve, often called an &amp;quot;eye stroke.&amp;quot; It typically appears as sudden, painless vision loss in one eye, and many people first notice it on waking. Some patients regain part of their sight. For many, the loss is permanent.&lt;/p&gt;</content:encoded></item><item><title>Building Your Teen&apos;s Social Media Claim: The Records That Matter</title><link>https://nulegal.com/blog/building-your-teens-social-media-claim-the-records-that-matter/</link><guid isPermaLink="true">https://nulegal.com/blog/building-your-teens-social-media-claim-the-records-that-matter/</guid><description>As social media addiction cases reach trial, the records that tie a claim to one child matter most. Here is what parents should save now, and what a law firm can request for them.</description><pubDate>Wed, 18 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Social media addiction cases against the major platforms have reached the stage where juries hear evidence. Verdicts have been reported. Individual cases against TikTok and Snapchat were reportedly settled shortly before they were set to be tried. We covered what those first trials mean for families still waiting in After the First Trials: What Comes Next for Pending Teen Claims.&lt;/p&gt;
&lt;p&gt;For a parent, the practical lesson is simpler. As cases move forward, the question shifts from what the platforms did in general to what happened to one specific child. Records answer that question. Most of them already exist somewhere, and some will disappear if nobody saves them.&lt;/p&gt;
&lt;p&gt;This guide covers what to save yourself and what a law firm can request for you.&lt;/p&gt;
&lt;p&gt;Federal cases are consolidated in MDL 3047, and California state cases are coordinated in JCCP 5255. The defendants include Meta (Instagram and Facebook), TikTok, Snap (Snapchat) and Google (YouTube). Plaintiffs allege the platforms were designed to keep young users engaged for as long as possible and that the companies failed to warn families about the risks of heavy use.&lt;/p&gt;</content:encoded></item><item><title>Bard PowerPort Settlement Talk: What a Claims Program Would Require</title><link>https://nulegal.com/blog/bard-powerport-settlement-talk-what-a-claims-program-would-require/</link><guid isPermaLink="true">https://nulegal.com/blog/bard-powerport-settlement-talk-what-a-claims-program-would-require/</guid><description>Reports say Bard PowerPort lawsuits may be moving toward settlement after split bellwether verdicts. Here is how mass tort settlement programs usually work and the records PowerPort claimants should gather now.</description><pubDate>Sat, 14 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;For most of the past year, news about Bard PowerPort lawsuits came out of courtrooms. Lately the coverage has turned. AboutLawsuits.com reported that lawyers have outlined a process for settling the cases after the bellwether trials, and Medtruth described the lawsuits as moving toward a possible settlement.&lt;/p&gt;
&lt;p&gt;That shift matters for a practical reason. If a settlement program is reached, it will ask each claimant to prove specific things on paper. People whose records are already in order tend to get through faster.&lt;/p&gt;
&lt;p&gt;As of mid-November 2026, the reports we have reviewed describe settlement as a possibility still under discussion. No deal has been publicly announced. Nothing here predicts that one will be, or what it would pay.&lt;/p&gt;
&lt;p&gt;Bellwether trials are test cases. Both sides watch how juries respond to the evidence, and those reactions shape negotiations over the cases still waiting.&lt;/p&gt;
&lt;p&gt;The PowerPort results so far point in different directions:&lt;/p&gt;</content:encoded></item><item><title>Can You Sue Uber Over a Driver&apos;s Assault if Drivers Aren&apos;t Employees?</title><link>https://nulegal.com/blog/can-you-sue-uber-over-a-drivers-assault-if-drivers-arent-employees/</link><guid isPermaLink="true">https://nulegal.com/blog/can-you-sue-uber-over-a-drivers-assault-if-drivers-arent-employees/</guid><description>The Uber MDL judge told jurors that drivers are not Uber&apos;s employees, yet riders&apos; claims against Uber still reached two juries. Here is what the court&apos;s orders say, and why the state of the ride matters.</description><pubDate>Sat, 14 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Yes. Riders have brought claims against Uber, and taken them to a jury, even though, in the first federal bellwether trial, the judge instructed the jury that drivers are not Uber&apos;s employees. In the first two federal bellwether trials, the claims against Uber that reached the jury did not depend on the driver being an employee. Which claims a rider can bring depends heavily on the law of the state where the ride happened.&lt;/p&gt;
&lt;p&gt;Everything below comes from orders and filings in MDL 3084, In re: Uber Technologies, Inc., Passenger Sexual Assault Litigation, before Judge Charles R. Breyer of the U.S. District Court for the Northern District of California. The claims in these cases are allegations, and Uber disputes them.&lt;/p&gt;
&lt;p&gt;He told the jury that drivers are not Uber&apos;s employees. The first federal bellwether case was tried in Phoenix, starting in January 2026, and in the amended final jury instructions Judge Breyer signed on February 2, 2026, he told the jurors that drivers &amp;quot;are not Uber&apos;s actual agents as a matter of law and are not Uber&apos;s employees.&amp;quot;&lt;/p&gt;</content:encoded></item><item><title>Did Duodenoscope Makers Follow FDA Rules? What the Record Shows</title><link>https://nulegal.com/blog/did-duodenoscope-makers-follow-fda-rules-what-the-record-shows/</link><guid isPermaLink="true">https://nulegal.com/blog/did-duodenoscope-makers-follow-fda-rules-what-the-record-shows/</guid><description>FDA warning letters say all three duodenoscope makers fell behind on contamination studies the agency ordered in 2015, and a federal case charged Olympus over infection reports it did not file. Here is what each record says and what it does not prove.</description><pubDate>Sat, 14 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Not always, by the FDA&apos;s own account. On March 9, 2018, the agency sent warning letters to Olympus, Fujifilm and Pentax, the companies that make the duodenoscopes sold in the United States, because their contamination studies were far behind the schedule it had ordered in 2015.&lt;/p&gt;
&lt;p&gt;Separately, a criminal case in federal court in New Jersey charged Olympus&apos;s Tokyo scope maker with selling scopes in the United States while infection reports it owed the FDA went unfiled.&lt;/p&gt;
&lt;p&gt;A duodenoscope is the reusable scope used in an ERCP, a procedure that reaches the bile duct and pancreas. Every record below is about what the companies owed the FDA. None of them is a finding that a particular patient&apos;s infection came from a particular scope, and that distinction matters when you read them.&lt;/p&gt;
&lt;p&gt;A manufacturer has 30 calendar days. Under 21 CFR 803.50, the clock starts when the company receives or becomes aware of information, &amp;quot;from any source,&amp;quot; that reasonably suggests a device it markets &amp;quot;may have caused or contributed to a death or serious injury.&amp;quot;&lt;/p&gt;</content:encoded></item><item><title>What Do Studies Show About Dupixent and Cutaneous T-Cell Lymphoma?</title><link>https://nulegal.com/blog/what-do-studies-show-about-dupixent-and-cutaneous-t-cell-lymphoma/</link><guid isPermaLink="true">https://nulegal.com/blog/what-do-studies-show-about-dupixent-and-cutaneous-t-cell-lymphoma/</guid><description>Some studies found cutaneous T-cell lymphoma diagnosed about four times as often after Dupixent, and others found no added lymphoma risk. What each study measured, and how the FDA and the MDL court are weighing it.</description><pubDate>Sat, 14 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Two large eczema studies found cutaneous T-cell lymphoma (CTCL) diagnosed about four times as often in people treated with Dupixent (dupilumab) as in similar patients who were not, and an asthma study found more T-cell lymphomas among dupilumab users. Two other studies, comparing it with other treatments, found no significant increase in lymphoma. None of this research proves that Dupixent causes lymphoma, and the authors of the studies that found a link say so themselves. Whether the science shows a causal link is the question the federal court handling the Dupixent lawsuits has set to take up first, with expert evidence scheduled into 2028.&lt;/p&gt;
&lt;p&gt;Below is what each study measured, and how the FDA and the court in MDL 3180 are treating the research. Everything here about the lawsuits describes allegations. No court has found that Dupixent caused anyone&apos;s lymphoma.&lt;/p&gt;
&lt;p&gt;Two 2024 studies of patients with atopic dermatitis (eczema) found CTCL recorded about four times as often among those who took dupilumab. Both drew on TriNetX, a database of de-identified health records, and both compared dupilumab patients with matched eczema patients who had not taken it.&lt;/p&gt;</content:encoded></item><item><title>Advocates Urge an FTC Probe of Roblox: What Families Should Know</title><link>https://nulegal.com/blog/advocates-urge-an-ftc-probe-of-roblox-what-families-should-know/</link><guid isPermaLink="true">https://nulegal.com/blog/advocates-urge-an-ftc-probe-of-roblox-what-families-should-know/</guid><description>Advocates have asked the FTC to investigate Roblox over child safety and marketing. Here is what a federal probe can and cannot do for families, and why a parent&apos;s own claim runs on a separate track.</description><pubDate>Wed, 11 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Reuters and CBS News have reported that child safety advocates are urging the Federal Trade Commission to investigate Roblox. Reuters described the request as covering both child safety and the way the platform markets itself.&lt;/p&gt;
&lt;p&gt;Read those stories closely. They report a request. Neither one reports that the FTC has opened an investigation, and we have not seen any public confirmation that it has.&lt;/p&gt;
&lt;p&gt;That difference matters for a parent deciding what to do next. A letter from advocates can draw attention to a problem, but it gives a family nothing to file and does nothing to stop a filing deadline.&lt;/p&gt;
&lt;p&gt;The request lands on top of a long run of state action. Reuters reported that Roblox agreed to pay $23 million to settle child safety investigations brought by Alabama and West Virginia, and Courthouse News reported the Alabama portion at $12.2 million. Reuters separately reported a $10 million Nevada settlement that included changes to the platform.&lt;/p&gt;
&lt;p&gt;Other states have gone to court instead. News outlets have reported lawsuits against Roblox by Arkansas (which also named Discord), Oklahoma, Nebraska and Indiana. KTLA reported that Los Angeles County filed its own suit, and the Ohio Attorney General&apos;s office has announced that it is seeking to lead a class action against the company.&lt;/p&gt;</content:encoded></item><item><title>Ozempic Gastroparesis Claims and the Court&apos;s Gastric Emptying Study Ruling</title><link>https://nulegal.com/blog/ozempic-gastroparesis-gastric-emptying-study-ruling/</link><guid isPermaLink="true">https://nulegal.com/blog/ozempic-gastroparesis-gastric-emptying-study-ruling/</guid><description>In August 2025 the judge over the federal GLP-1 lawsuits ruled that a gastroparesis claim needs a diagnosis from a properly performed gastric emptying study. What the order says, and what the court has not yet decided.</description><pubDate>Tue, 10 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you are claiming gastroparesis in the federal GLP-1 lawsuits, your diagnosis has to rest on a gastric emptying study. On August 15, 2025, Judge Karen Spencer Marston, who oversees the consolidated cases in the Eastern District of Pennsylvania as MDL 3094, ordered that &amp;quot;Any Plaintiff claiming to suffer (or have suffered) from gastroparesis, must show that their diagnosis is based on a properly performed gastric emptying study (scintigraphy, breath test, or WMC).&amp;quot; That sentence is paragraph 4 of the court&apos;s order, Document 468 on the MDL docket, 24-md-3094. A diagnosis made from symptoms alone does not meet it.&lt;/p&gt;
&lt;p&gt;It ruled that a gastroparesis diagnosis must rest on a properly performed gastric emptying study, and it excluded the two plaintiffs&apos; experts who said otherwise. The order settled what the court calls Cross Cutting Issue No. 1: whether gastroparesis can be reliably diagnosed without objective testing. The judge held an evidentiary hearing on May 14, 2025 and heard argument on May 19, 2025. In the order she granted the drug makers&apos; motions to exclude the opinions of two experts for the plaintiffs, Dr. Daniel Raines and Dr. Eliot Siegel, who would have testified that gastroparesis can be diagnosed without a test done at the time. She denied the plaintiffs&apos; motion to exclude the drug makers&apos; expert, Dr. Linda Nguyen.&lt;/p&gt;</content:encoded></item><item><title>Questions to Ask a Mass Tort Attorney Before You Hire One</title><link>https://nulegal.com/blog/questions-to-ask-a-mass-tort-attorney-before-hiring/</link><guid isPermaLink="true">https://nulegal.com/blog/questions-to-ask-a-mass-tort-attorney-before-hiring/</guid><description>What to ask a mass tort lawyer before you sign: the fee, case costs if you lose, fee splits between firms and who tries your case, with California&apos;s rule for each.</description><pubDate>Sat, 07 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Before you sign with a lawyer for a drug, medical device, online platform or rideshare injury, ask how the fee works, what you owe for case costs if the case loses, which firms share the fee, who will actually try your case, and how you will hear about it. A careful firm answers each of those plainly and puts the money answers in writing, because California law requires much of that writing anyway.&lt;/p&gt;
&lt;p&gt;This guide gives the questions, what a straight answer sounds like, and the rule behind each one. One disclosure first: attorney Ashkaan Hassan reviews claims for NuLegal, and, with the client&apos;s written consent, introduces a qualified case to a trial firm that specializes in mass torts. Any fee NuLegal receives is paid out of that trial firm&apos;s fee, never from your recovery. So the questions below about firms sharing a case apply to us too.&lt;/p&gt;
&lt;p&gt;The fee is a percentage you agree on, and in California it has to be in a signed, written contract. Ask for the number, whether it changes if the case goes to trial, and your copy of the agreement.&lt;/p&gt;</content:encoded></item><item><title>School District Bellwethers and Your Family&apos;s Social Media Claim</title><link>https://nulegal.com/blog/school-district-bellwethers-and-your-familys-social-media-claim/</link><guid isPermaLink="true">https://nulegal.com/blog/school-district-bellwethers-and-your-familys-social-media-claim/</guid><description>School district cases were reported as the first bellwether group in the social media addiction MDL. This post explains how those cases differ from a family&apos;s own claim for a harmed teen and why parents should still watch them.</description><pubDate>Sat, 07 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you have been reading about the social media addiction litigation because of your child, you have probably seen headlines about school districts suing the platforms. It can look as though the litigation now belongs to institutions. It does not.&lt;/p&gt;
&lt;p&gt;Families have filed their own lawsuits, and some school districts have brought separate claims against Meta (which owns Instagram and Facebook), TikTok, Snap and YouTube. Reporting this year from AboutLawsuits.com said that school district cases would be the first group tried as bellwethers in the federal multidistrict litigation, MDL 3047.&lt;/p&gt;
&lt;p&gt;This post explains how those district cases differ from a claim you might bring for your own child. It also explains why we think parents should follow them anyway.&lt;/p&gt;
&lt;p&gt;The districts allege that design features of these platforms contributed to a youth mental health burden that schools have had to absorb. They point to money spent on counseling staff and to disruption in classrooms.&lt;/p&gt;
&lt;p&gt;The companies dispute those allegations. The cases remain active, and what a complaint says is what a party has to prove at trial.&lt;/p&gt;</content:encoded></item><item><title>Scope Infection Claim? You Don&apos;t Need to Know the Manufacturer</title><link>https://nulegal.com/blog/scope-infection-claim-you-dont-need-to-know-the-manufacturer/</link><guid isPermaLink="true">https://nulegal.com/blog/scope-infection-claim-you-dont-need-to-know-the-manufacturer/</guid><description>After an infection from an ERCP or other scope procedure, you don&apos;t need the scope maker or the bacteria&apos;s name to ask for a review. Here is where those details are recorded and why your state&apos;s law decides so much.</description><pubDate>Wed, 04 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Many people who got a serious infection after an ERCP or another scope procedure think they need answers before they can talk to a lawyer. Which company made the scope? What was the bacteria called? If they were moved between hospitals during a hard recovery, they may not even be sure where the procedure took place.&lt;/p&gt;
&lt;p&gt;You don&apos;t need any of that. A claimant does not need to know the scope&apos;s manufacturer, its model, the organism, or even the facility. Hospitals and labs keep those details in their records, and finding them is the legal team&apos;s work after you reach out.&lt;/p&gt;
&lt;p&gt;Recent reporting has covered new lawsuits against Olympus over sepsis after ERCP and over a fatal VRE infection. Claims have also been brought against Fujifilm and Pentax. Each case rests on the allegation that a reusable flexible scope carried drug-resistant bacteria from one patient to another. No court has found that any manufacturer&apos;s design caused the infections at issue.&lt;/p&gt;
&lt;p&gt;Most of the litigation covered on this site goes through a consolidated proceeding. Scope infection claims don&apos;t. There is no MDL and no class action for them. Each claim is filed on its own, in a state or federal court.&lt;/p&gt;</content:encoded></item><item><title>Dupixent Lawsuits Centralized in New Jersey: What the MDL Means</title><link>https://nulegal.com/blog/dupixent-lawsuits-centralized-in-new-jersey-what-the-mdl-means/</link><guid isPermaLink="true">https://nulegal.com/blog/dupixent-lawsuits-centralized-in-new-jersey-what-the-mdl-means/</guid><description>In June 2026, federal Dupixent lymphoma lawsuits were centralized in New Jersey. This post covers what the MDL handles, what it does not decide, and why a CTCL diagnosis before treatment may not rule you out.</description><pubDate>Wed, 28 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;In June 2026, the Judicial Panel on Multidistrict Litigation centralized federal lawsuits alleging that Dupixent (dupilumab) is linked to cutaneous T-cell lymphoma. They now sit in one proceeding, MDL 3180, in the U.S. District Court for the District of New Jersey. The named defendants are Sanofi and Regeneron, the companies behind the drug.&lt;/p&gt;
&lt;p&gt;If you took Dupixent for eczema or atopic dermatitis and were later diagnosed with a lymphoma of the skin, this order will shape how a federal claim moves from here. It is also easy to misread. Some coverage makes it sound as if the panel looked at the science and found something.&lt;/p&gt;
&lt;p&gt;It did not.&lt;/p&gt;
&lt;p&gt;A multidistrict litigation brings cases that share common factual questions before a single federal judge for the pretrial phase. In practice that judge oversees:&lt;/p&gt;
&lt;p&gt;Each case stays individual. An MDL works differently from a class action. Nobody is appointed to speak for you as a class representative, and your own diagnosis, treatment dates and medical records will carry your claim.&lt;/p&gt;</content:encoded></item><item><title>Suing the Driver and Uber: Who a Survivor&apos;s Lawsuit Names</title><link>https://nulegal.com/blog/suing-the-driver-and-uber-who-a-survivors-lawsuit-names/</link><guid isPermaLink="true">https://nulegal.com/blog/suing-the-driver-and-uber-who-a-survivors-lawsuit-names/</guid><description>Many Uber sexual assault lawsuits name both the driver and the company. Here is how those claims differ, what the trials so far show, and what survivors do not need to have ready before asking for a review.</description><pubDate>Sat, 24 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;When a rider alleges that an Uber driver sexually assaulted them, the lawsuit that follows often names two defendants: the driver and Uber Technologies. That pairing confuses people. Survivors reasonably ask why a company belongs in a case about something one person allegedly did.&lt;/p&gt;
&lt;p&gt;The two claims ask different questions. The claim against the driver is about the driver&apos;s own alleged conduct during the ride. The claims against Uber are about the company&apos;s alleged choices before that ride ever started, including how it screened drivers and which safety measures it did or did not put in place.&lt;/p&gt;
&lt;p&gt;A court or jury can treat those allegations separately. Knowing the difference explains a good deal of what has happened in this litigation so far.&lt;/p&gt;
&lt;p&gt;A recent CBS News report described a Cicero woman who filed a lawsuit against both Uber and the driver she accuses of sexually assaulting her. Filings like that one tend to follow a familiar shape. The complaint makes allegations about the driver&apos;s conduct, then a second set of allegations about what Uber allegedly knew, did, or failed to do.&lt;/p&gt;</content:encoded></item><item><title>Skin Biopsies Before Dupixent: What the Recommendation Means for Patients</title><link>https://nulegal.com/blog/skin-biopsies-before-dupixent-what-the-recommendation-means-for-patients/</link><guid isPermaLink="true">https://nulegal.com/blog/skin-biopsies-before-dupixent-what-the-recommendation-means-for-patients/</guid><description>Some experts have reportedly recommended skin biopsies before starting Dupixent. Here is what that discussion means for patients later diagnosed with cutaneous T-cell lymphoma, and for the two claims being pleaded against Sanofi and Regeneron.</description><pubDate>Wed, 21 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Dupixent (dupilumab) is widely prescribed for moderate-to-severe eczema, also called atopic dermatitis. Recent coverage reports that some experts now recommend a skin biopsy before a patient starts Dupixent. The concern is about telling ordinary eczema apart from an early cutaneous T-cell lymphoma (CTCL).&lt;/p&gt;
&lt;p&gt;This post explains what that discussion is about and why it matters if you or a family member was diagnosed with CTCL after using Dupixent. It also covers why a diagnosis made before you started the drug does not automatically rule you out.&lt;/p&gt;
&lt;p&gt;The litigation is at an early stage, and very little has been established. Everything below about the lawsuits describes allegations under examination. None of it is a finding by any court.&lt;/p&gt;
&lt;p&gt;CTCL is a group of rare cancers that start in white blood cells called T cells and show up first in the skin. The two forms named most often in these lawsuits are:&lt;/p&gt;
&lt;p&gt;According to the National Cancer Institute, early mycosis fungoides can look like other common skin conditions, including eczema and psoriasis. Doctors usually need a biopsy, and sometimes more than one, to confirm the diagnosis. That overlap is at the heart of the biopsy discussion.&lt;/p&gt;</content:encoded></item><item><title>Uber Accused of Hiding Assault Numbers: What It Means for Survivors</title><link>https://nulegal.com/blog/uber-accused-of-hiding-assault-numbers-what-it-means-for-survivors/</link><guid isPermaLink="true">https://nulegal.com/blog/uber-accused-of-hiding-assault-numbers-what-it-means-for-survivors/</guid><description>Forbes reported a new lawsuit accusing Uber of covering up sexual assault numbers. Here is why safety data matters in passenger claims, and what the allegations do not change for survivors.</description><pubDate>Sat, 17 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Forbes has reported on a new lawsuit that accuses Uber of covering up the number of sexual assaults reported on its platform. Those accusations are allegations. No court has found them true, and Uber is entitled to contest them.&lt;/p&gt;
&lt;p&gt;For survivors, the story matters for a narrower reason than the headline suggests. Much of the passenger litigation against Uber turns on what the company knew about assault risk and when it knew it. Figures about reported incidents sit close to the center of that question.&lt;/p&gt;
&lt;p&gt;This post explains why safety data keeps coming up in these cases and what the new allegations do (and do not) change for a survivor deciding whether to ask about a claim.&lt;/p&gt;
&lt;p&gt;Federal claims by riders are coordinated in MDL 3084 before Judge Charles R. Breyer in the U.S. District Court for the Northern District of California. Claims filed in California state court are coordinated separately in JCCP 5188.&lt;/p&gt;
&lt;p&gt;Riders in both proceedings allege they were sexually assaulted by an Uber driver. The claims against the company generally rest on two theories:&lt;/p&gt;</content:encoded></item><item><title>Dupixent MDL Leadership Fight: What Early Organization Means for Patients</title><link>https://nulegal.com/blog/dupixent-mdl-leadership-fight-what-early-organization-means-for-patients/</link><guid isPermaLink="true">https://nulegal.com/blog/dupixent-mdl-leadership-fight-what-early-organization-means-for-patients/</guid><description>Lawyers are seeking leadership roles in the Dupixent lymphoma MDL against Sanofi and Regeneron. Learn what this early procedural step means for patients diagnosed with CTCL, mycosis fungoides, or Sézary syndrome.</description><pubDate>Wed, 14 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Recent reporting by AboutLawsuits.com describes plaintiffs&apos; lawyers seeking leadership positions in the federal litigation over Dupixent (dupilumab) and cutaneous T-cell lymphoma (CTCL). These lawsuits name Sanofi and Regeneron and have been consolidated in federal court in New Jersey, according to reports including one from Lieff Cabraser. The proceeding is MDL 3180, which was centralized in June 2026.&lt;/p&gt;
&lt;p&gt;If you or a family member was diagnosed with CTCL, mycosis fungoides, or Sézary syndrome after receiving Dupixent for eczema or atopic dermatitis, these headlines may raise questions. This post explains what the leadership process is, what it does not mean, and why the stage the litigation is in matters.&lt;/p&gt;
&lt;p&gt;When the Judicial Panel on Multidistrict Litigation centralizes cases, it sends similar federal lawsuits to one judge so that pretrial matters such as evidence exchange and expert challenges can be handled together. This is a case-management decision.&lt;/p&gt;
&lt;p&gt;It is important to be clear about one point:&lt;/p&gt;</content:encoded></item><item><title>Uber MDL or California JCCP: Where Survivor Claims Are Heard</title><link>https://nulegal.com/blog/uber-mdl-or-california-jccp-where-survivor-claims-are-heard/</link><guid isPermaLink="true">https://nulegal.com/blog/uber-mdl-or-california-jccp-where-survivor-claims-are-heard/</guid><description>Uber sexual assault claims move through a federal MDL and a separate California state proceeding. Here is how the two tracks differ and where Lyft rider claims are handled.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Survivors who start reading about the Uber litigation run into two labels almost right away: MDL 3084 and JCCP 5188. Both involve riders who allege they were sexually assaulted by an Uber driver.&lt;/p&gt;
&lt;p&gt;Both also center on the same core allegations against Uber Technologies: that its driver background checks fell short, and that it chose not to adopt safety measures plaintiffs say were available.&lt;/p&gt;
&lt;p&gt;They are separate proceedings in separate court systems, though. Which one a claim lands in decides the judge and the trial calendar that apply to it.&lt;/p&gt;
&lt;p&gt;This post walks through how each track is organized and where Lyft claims fit. Every claim described here is an allegation, and Uber disputes them.&lt;/p&gt;
&lt;p&gt;A multidistrict litigation, or MDL, gathers similar federal lawsuits in front of one judge for pretrial work. The authority comes from 28 U.S.C. § 1407, and the Judicial Panel on Multidistrict Litigation decides which cases get grouped and where they go.&lt;/p&gt;</content:encoded></item><item><title>Dupixent Lymphoma MDL Leadership: What Early-Stage Litigation Means for Patients</title><link>https://nulegal.com/blog/dupixent-lymphoma-mdl-leadership-what-early-stage-litigation-means-for-patients/</link><guid isPermaLink="true">https://nulegal.com/blog/dupixent-lymphoma-mdl-leadership-what-early-stage-litigation-means-for-patients/</guid><description>Attorneys have reportedly sought leadership roles in the newly centralized Dupixent lymphoma MDL. Here is what this early stage means, what both pleaded theories allege, and why a diagnosis before Dupixent does not automatically rule someone out.</description><pubDate>Wed, 07 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Lawsuits filed against Sanofi and Regeneron over Dupixent (dupilumab) and cutaneous T-cell lymphoma (CTCL) were centralized in June 2026 into MDL 3180 in the District of New Jersey. AboutLawsuits.com has reported that plaintiffs&apos; attorneys are now seeking leadership positions in that MDL.&lt;/p&gt;
&lt;p&gt;That may sound like inside-baseball, but it tells patients something useful: this litigation is at its very beginning. Very little has been established as fact. No bellwether trials have taken place, and no court has decided whether Dupixent causes, accelerates, or masks any lymphoma.&lt;/p&gt;
&lt;p&gt;This post explains what the leadership stage involves, what the lawsuits allege, and what it means for people who are trying to decide whether to come forward.&lt;/p&gt;
&lt;p&gt;The Judicial Panel on Multidistrict Litigation centralizes cases when many lawsuits share common factual questions. Its job is to make the litigation efficient: one judge handling discovery and pretrial rulings instead of dozens of judges duplicating work.&lt;/p&gt;
&lt;p&gt;The Panel&apos;s decision to centralize Dupixent cases is not a finding that Dupixent caused anyone&apos;s cancer. It is not a ruling on the merits of any claim. It is a case-management step, and it should be read that way.&lt;/p&gt;</content:encoded></item><item><title>Uber&apos;s Texas Bellwether Settlement: What It Means for Other Survivors</title><link>https://nulegal.com/blog/ubers-texas-bellwether-settlement-what-it-means-for-other-survivors/</link><guid isPermaLink="true">https://nulegal.com/blog/ubers-texas-bellwether-settlement-what-it-means-for-other-survivors/</guid><description>In October 2026 Uber settled a Texas bellwether sexual assault case before opening statements. Here is what a last-minute settlement tells survivors with pending or new claims, and where it tells them very little.</description><pubDate>Sat, 03 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;In October 2026, Uber settled a Texas bellwether case in the federal passenger sexual assault litigation before opening statements, according to reporting by Bloomberg Law and Top Class Actions. The case had been set to go forward as the third bellwether trial.&lt;/p&gt;
&lt;p&gt;If you are a survivor with a claim on file, or one you have been turning over in your mind, you have probably seen the headlines. Some coverage reads the settlement as a sign Uber is ready to pay everyone. Some reads it as a sign no case will reach a jury again.&lt;/p&gt;
&lt;p&gt;Both readings go further than the facts allow. This post covers what a settlement on the eve of a bellwether trial means for other survivors, and where it tells you very little.&lt;/p&gt;
&lt;p&gt;Federal cases are consolidated as MDL 3084 in the U.S. District Court for the Northern District of California, before Judge Charles R. Breyer. California state-court cases are coordinated separately in JCCP 5188.&lt;/p&gt;
&lt;p&gt;In both proceedings, riders allege they were sexually assaulted by an Uber driver and that the company&apos;s background checks and safety measures fell short. Uber disputes those claims. They remain allegations, and a jury verdict in one case decides that case alone.&lt;/p&gt;</content:encoded></item><item><title>No MDL for Scope Infection Lawsuits: Why Your State&apos;s Law Matters</title><link>https://nulegal.com/blog/no-mdl-for-scope-infection-lawsuits-why-your-states-law-matters/</link><guid isPermaLink="true">https://nulegal.com/blog/no-mdl-for-scope-infection-lawsuits-why-your-states-law-matters/</guid><description>Contaminated endoscope infection claims are filed individually, not through an MDL or class action. Here is what that means for patients and families, and why state law plays such a central role.</description><pubDate>Wed, 30 Sep 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Many people look into a lawsuit after an infection that followed an endoscopy procedure. They often expect to find one large consolidated case they can join. Most mass tort coverage, including much of what appears on this site, describes multidistrict litigation (MDL), bellwether trials and coordinated settlement programs.&lt;/p&gt;
&lt;p&gt;Contaminated endoscope infection claims do not work that way. No MDL and no class action exist for these claims. Lawsuits against scope manufacturers such as Olympus, Fujifilm and Pentax are filed individually in state and federal courts, one patient or one family at a time.&lt;/p&gt;
&lt;p&gt;This difference shapes almost every part of a claim. It also means the law of the claimant&apos;s own state matters much more than it does in a consolidated proceeding.&lt;/p&gt;
&lt;p&gt;Recent reporting describes separate lawsuits rather than one coordinated docket. Infection Control Today reported on a new Olympus lawsuit that alleges a fatal VRE (vancomycin-resistant Enterococcus) infection linked to a reusable duodenoscope.&lt;/p&gt;</content:encoded></item><item><title>Uber&apos;s Defense Questions and the Rules That Protect Survivors</title><link>https://nulegal.com/blog/ubers-defense-questions-and-the-rules-that-protect-survivors/</link><guid isPermaLink="true">https://nulegal.com/blog/ubers-defense-questions-and-the-rules-that-protect-survivors/</guid><description>After a New York Times report on Uber&apos;s defense strategy, here is how Federal Rule of Evidence 412, California law, and protective orders limit questions about a survivor&apos;s clothing and sexual history in Uber cases.</description><pubDate>Sat, 26 Sep 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;The New York Times recently published a report on how Uber defends rider sexual assault lawsuits. Its headline was &amp;quot;Uber&apos;s Strategy for Fighting Sexual Assault Suits: &apos;What Were You Wearing?&apos;&amp;quot; For a survivor deciding whether to come forward, that headline lands hard.&lt;/p&gt;
&lt;p&gt;A fair question follows from it. If you file a claim, what can Uber&apos;s lawyers actually ask you, and what stops them?&lt;/p&gt;
&lt;p&gt;This post covers the rules that limit those questions and the protections a survivor can ask for. It does not describe any assault, and it does not name anyone who has filed.&lt;/p&gt;
&lt;p&gt;Federal claims from riders who allege they were sexually assaulted by an Uber driver are consolidated in MDL 3084 before Judge Charles R. Breyer in the U.S. District Court for the Northern District of California. California state-court claims are coordinated separately in JCCP 5188. The lawsuits allege that Uber&apos;s background checks and safety measures fell short. Uber disputes those allegations.&lt;/p&gt;
&lt;p&gt;Consolidation is a case-management step. The Judicial Panel on Multidistrict Litigation groups similar federal cases so pretrial work happens once. That decision says nothing about whether any individual claim is true.&lt;/p&gt;</content:encoded></item><item><title>Split Bard PowerPort Bellwether Verdicts: What Patients Should Know</title><link>https://nulegal.com/blog/split-bard-powerport-bellwether-verdicts-what-patients-should-know/</link><guid isPermaLink="true">https://nulegal.com/blog/split-bard-powerport-bellwether-verdicts-what-patients-should-know/</guid><description>Bard reportedly won the first PowerPort bellwether trial, and a jury in the second reportedly returned a $40 million verdict. Here is what bellwether results can and cannot tell port catheter patients about their own claims.</description><pubDate>Wed, 23 Sep 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Patients following the Bard PowerPort litigation have seen two very different outcomes in a short period. According to reporting from Law.com, C.R. Bard won a defense verdict in the first bellwether trial over its PowerPort implanted port device. A second bellwether trial followed, and Law.com and AboutLawsuits.com have reported that the jury in that trial returned a $40 million verdict for the plaintiff.&lt;/p&gt;
&lt;p&gt;If you or a family member had a port catheter implanted for chemotherapy or other long-term treatment and later had a complication, you may be wondering what these results mean for you. This post explains what bellwether trials are, why the results can differ from one trial to the next, and why neither verdict decides anyone else&apos;s claim.&lt;/p&gt;
&lt;p&gt;When many similar lawsuits are consolidated before one federal judge, the court often schedules a small number of bellwether trials. These are individual cases chosen to go to trial first. Each involves one plaintiff, that plaintiff&apos;s medical history, and that plaintiff&apos;s evidence.&lt;/p&gt;</content:encoded></item><item><title>What Uber&apos;s Trial Results So Far Mean for Survivors Weighing a Claim</title><link>https://nulegal.com/blog/what-ubers-trial-results-so-far-mean-for-survivors-weighing-a-claim/</link><guid isPermaLink="true">https://nulegal.com/blog/what-ubers-trial-results-so-far-mean-for-survivors-weighing-a-claim/</guid><description>Uber won the first California state-court trial, two juries returned plaintiff verdicts, and a Texas bellwether settled in October 2026. Here is what that dated record means for survivors weighing a claim.</description><pubDate>Sat, 19 Sep 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;In October 2026, Uber settled a bellwether sexual assault case in Texas before opening statements began, according to reporting from Bloomberg Law and Top Class Actions. It was the third bellwether case set for trial in the federal litigation over rider sexual assault claims.&lt;/p&gt;
&lt;p&gt;The jury never heard a single argument.&lt;/p&gt;
&lt;p&gt;If you are a survivor who has been following these trials, you may be asking what any of it means for you. This post lays out each result so far with its date and its source, puts the defense win right beside the plaintiff verdicts, and explains what those outcomes can and cannot tell you about your own situation.&lt;/p&gt;
&lt;p&gt;Federal claims against Uber Technologies are coordinated in MDL 3084, assigned to Judge Charles R. Breyer of the U.S. District Court for the Northern District of California. Claims filed in California state court proceed separately in a coordinated proceeding, JCCP 5188.&lt;/p&gt;
&lt;p&gt;A multidistrict litigation, or MDL, gathers similar federal cases in front of one judge for pretrial work such as evidence exchange and motions. The Judicial Panel on Multidistrict Litigation decides when cases get centralized this way. The Panel&apos;s decision concerns efficiency and makes no ruling on whether Uber did anything wrong. Every claim in these proceedings remains an allegation unless a jury or judge decides it.&lt;/p&gt;</content:encoded></item><item><title>Dupixent Lymphoma Lawsuits Centralized: What the New MDL Means</title><link>https://nulegal.com/blog/dupixent-lymphoma-lawsuits-centralized-what-the-new-mdl-means/</link><guid isPermaLink="true">https://nulegal.com/blog/dupixent-lymphoma-lawsuits-centralized-what-the-new-mdl-means/</guid><description>Federal Dupixent cutaneous T-cell lymphoma lawsuits have been centralized in New Jersey. Learn what centralization means, what it does not decide, and the two allegations being pleaded, including delayed diagnosis.</description><pubDate>Wed, 16 Sep 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Federal lawsuits alleging a connection between Dupixent (dupilumab) and cutaneous T-cell lymphoma have been centralized into a single multidistrict litigation. The MDL was created in June 2026 and assigned to the U.S. District Court for the District of New Jersey. Sanofi and Regeneron are named as defendants.&lt;/p&gt;
&lt;p&gt;If you or a family member used Dupixent for eczema or atopic dermatitis and later received a lymphoma diagnosis, this news may raise more questions than it answers. This post explains what centralization is, what it is not, and what the lawsuits allege at this early stage.&lt;/p&gt;
&lt;p&gt;This litigation is at its beginning, and very little has been established. The claims described below are allegations that no court has yet tested.&lt;/p&gt;
&lt;p&gt;Centralization decisions come from the Judicial Panel on Multidistrict Litigation, a group of federal judges who decide whether similar cases filed in different districts should be handled together before trial. The Panel&apos;s authority comes from a federal statute, 28 U.S.C. § 1407, which allows cases to be transferred when they share common questions of fact and coordination would promote convenience and efficiency.&lt;/p&gt;</content:encoded></item><item><title>Diagnosed Before Dupixent? The Delayed-Diagnosis Claim Explained</title><link>https://nulegal.com/blog/diagnosed-before-dupixent-the-delayed-diagnosis-claim-explained/</link><guid isPermaLink="true">https://nulegal.com/blog/diagnosed-before-dupixent-the-delayed-diagnosis-claim-explained/</guid><description>Dupixent lymphoma lawsuits plead two separate theories, and only one involves the drug allegedly causing cancer. Here is what the delayed-diagnosis or &quot;masking&quot; allegation involves and why a diagnosis that came before or during treatment does not automatically rule someone out.</description><pubDate>Wed, 09 Sep 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;People who contact us about Dupixent (dupilumab) and cutaneous T-cell lymphoma frequently open with a version of the same sentence: &amp;quot;I don&apos;t think I qualify, because my lymphoma was found while I was still on the drug&amp;quot;, or, sometimes, &amp;quot;my dermatologist thinks I probably had it before I ever started.&amp;quot;&lt;/p&gt;
&lt;p&gt;That assumption is worth pausing on. The lawsuits filed to date against Sanofi and Regeneron plead two distinct theories, and only one of them depends on the drug having started a cancer that was not there before. A post (or a conversation) that covers only the first theory gives an incomplete picture of who the litigation is written to include.&lt;/p&gt;
&lt;p&gt;This article walks through both theories, in plain language, and explains why the timing of a diagnosis is a question for the records and the experts rather than something a patient should decide against themselves at the outset.&lt;/p&gt;
&lt;p&gt;The complaints reported to date advance these allegations:&lt;/p&gt;
&lt;p&gt;Both are allegations under examination in active litigation. Neither has been established as a proven biological mechanism, and no court has determined that dupilumab causes, accelerates, or conceals lymphoma in anyone. Reported filings, including one described by AboutLawsuits.com as alleging that Dupixent &amp;quot;caused T-cell lymphoma or rapidly progressed&amp;quot; an existing cancer, reflect what plaintiffs claim, not what has been decided.&lt;/p&gt;</content:encoded></item><item><title>Diagnosed Before Dupixent? Why Masking Claims Still Matter</title><link>https://nulegal.com/blog/diagnosed-before-dupixent-why-masking-claims-still-matter/</link><guid isPermaLink="true">https://nulegal.com/blog/diagnosed-before-dupixent-why-masking-claims-still-matter/</guid><description>Dupixent lawsuits plead two separate theories: that the drug may cause or accelerate cutaneous T-cell lymphoma, and that it may mask early lymphoma symptoms and delay diagnosis. Here is what that second theory means for patients who assume their timeline rules them out.</description><pubDate>Wed, 02 Sep 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;When families first read about the Dupixent (dupilumab) lymphoma litigation, many of them do a quick mental calculation and stop there. They remember that the skin biopsy came back before the injections started, or that the diagnosis arrived so soon after starting treatment that it seemed impossible for the drug to be involved. They conclude the litigation is not about them, and they never ask anyone.&lt;/p&gt;
&lt;p&gt;That conclusion is often premature. The lawsuits being pursued against Sanofi and Regeneron do not rest on a single theory. Two separate allegations are being pleaded, and the second one specifically concerns patients whose lymphoma may already have been present when treatment began.&lt;/p&gt;
&lt;p&gt;None of this means any particular person has a claim, and none of it means the allegations have been proven. It means the timing question is more complicated than most people assume, and it is worth asking rather than answering yourself.&lt;/p&gt;
&lt;p&gt;The first limb is the one that gets written about most: plaintiffs allege that Dupixent may cause or accelerate a cutaneous T-cell lymphoma (CTCL) in patients treated for eczema or atopic dermatitis. Reported filings have described diagnoses of mycosis fungoides and Sézary syndrome following treatment, including at least one case reported by legal trade press in which the diagnosis came after less than a year of use.&lt;/p&gt;</content:encoded></item><item><title>Depo-Provera Settlement Reports: What Meningioma Claimants Should Know</title><link>https://nulegal.com/blog/depo-provera-settlement-reports-what-meningioma-claimants-should-know/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-settlement-reports-what-meningioma-claimants-should-know/</guid><description>Legal trade press has reported that Pfizer reached an agreement to resolve the federal Depo-Provera meningioma litigation. Here is what a settlement agreement does and does not mean, and how mass tort settlement programs generally work.</description><pubDate>Wed, 26 Aug 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Legal trade publications have reported that Pfizer reached an agreement intended to resolve claims in the federal multidistrict litigation brought by women who allege they developed meningioma brain tumors after receiving Depo-Provera contraceptive injections. Coverage of that reported agreement has appeared across outlets that follow mass tort dockets.&lt;/p&gt;
&lt;p&gt;If you or someone in your family has a meningioma diagnosis and a history of Depo-Provera use, that news probably raised more questions than it answered. Does a settlement mean the case is over? Does it mean the drug caused the tumor? Can someone still come forward?&lt;/p&gt;
&lt;p&gt;This post walks through what a reported settlement agreement in a mass tort generally means, what it does not mean, and what usually happens next. None of this is a prediction about any individual claim. No lawyer can tell you what a specific case is worth, and anyone who does is guessing.&lt;/p&gt;
&lt;p&gt;This distinction matters, and it gets blurred constantly in headlines.&lt;/p&gt;
&lt;p&gt;When a manufacturer agrees to resolve a group of claims, it is making a business decision to end litigation exposure. It is not conceding that the product caused anyone&apos;s injury, and no judge or jury has ruled that it did. Settlement agreements in pharmaceutical litigation routinely include express denials of liability.&lt;/p&gt;</content:encoded></item><item><title>Roblox Terms of Service and Arbitration: What Parents Should Know</title><link>https://nulegal.com/blog/roblox-terms-of-service-and-arbitration-what-parents-should-know/</link><guid isPermaLink="true">https://nulegal.com/blog/roblox-terms-of-service-and-arbitration-what-parents-should-know/</guid><description>Roblox has reportedly raised its terms of service as a defense in a child-safety case, arguing a young user agreed to those terms. Here is what arbitration clauses and minors&apos; contract rules mean for parents and guardians weighing a claim.</description><pubDate>Wed, 19 Aug 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you are a parent or guardian who has been reading about Roblox child-safety litigation, you may have seen headlines reporting that Roblox Corporation argued a young user (reportedly an eight-year-old) had agreed to the platform&apos;s terms and, by doing so, given up certain rights. Local reporting, including coverage by the Courier-Journal, described that argument being raised in a wrongful death case.&lt;/p&gt;
&lt;p&gt;That kind of argument can be jarring to read. It is worth understanding what it actually is. A terms-of-service defense is a procedural argument about where and how a dispute gets decided, not a statement about whether a child was harmed, and not a court finding that anything alleged is untrue. Companies raise these arguments early, and courts decide them separately from the underlying facts.&lt;/p&gt;
&lt;p&gt;This post explains what those clauses typically say, why they matter to families, and what a parent can do now. Nothing here predicts how any court will rule, and no outcome in any case is guaranteed.&lt;/p&gt;</content:encoded></item><item><title>Depo-Provera Settlement Reports: What They Mean for Claimants</title><link>https://nulegal.com/blog/depo-provera-settlement-reports-what-they-mean-for-claimants/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-settlement-reports-what-they-mean-for-claimants/</guid><description>Reports describe an agreement to resolve federal Depo-Provera meningioma claims. Here is what a settlement agreement means at this stage, what remains unresolved, and what records matter if you took the shot and were later diagnosed with a meningioma.</description><pubDate>Wed, 12 Aug 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you took Depo-Provera and were later diagnosed with a meningioma, you have probably seen headlines announcing a settlement. Several legal news outlets have reported that Pfizer reached an agreement intended to resolve claims in the federal Depo-Provera brain tumor multidistrict litigation, and consumer legal sites have followed with pages describing eligibility and payouts.&lt;/p&gt;
&lt;p&gt;That reporting is worth taking seriously. It is also worth reading carefully. A reported agreement to resolve litigation is a negotiated business decision between parties. It is not a court finding that Depo-Provera causes meningiomas, and it is not a jury verdict assigning fault. Pfizer has denied the allegations throughout this litigation, and a settlement, where one exists, typically resolves claims without any admission of liability.&lt;/p&gt;
&lt;p&gt;This post explains what a settlement agreement generally means at this stage of a mass tort, so you can evaluate what you are reading against what is actually known.&lt;/p&gt;
&lt;p&gt;People often assume that &amp;quot;settlement reached&amp;quot; means checks are being written. In multidistrict litigation, it almost never works that way. An agreement in principle is usually the first step in a long administrative process that can include:&lt;/p&gt;</content:encoded></item><item><title>GLP-1 Vision Loss Claims: What NAION Lawsuits Allege</title><link>https://nulegal.com/blog/glp-1-vision-loss-claims-what-naion-lawsuits-allege/</link><guid isPermaLink="true">https://nulegal.com/blog/glp-1-vision-loss-claims-what-naion-lawsuits-allege/</guid><description>Lawsuits have been reported alleging that GLP-1 medications like Ozempic and Wegovy are linked to NAION, a sudden form of optic nerve injury. Here is what the research reports, what plaintiffs allege, and what the symptoms look like.</description><pubDate>Wed, 05 Aug 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Most of the early coverage of GLP-1 injury lawsuits focused on the digestive system: gastroparesis, bowel obstruction, gallbladder disease, and pancreatitis. Over the past year, a different category of claim has appeared in news reports: sudden, often permanent vision loss attributed to a condition called NAION.&lt;/p&gt;
&lt;p&gt;News outlets have reported individual lawsuits filed by people who say they lost vision in one eye while taking a GLP-1 medication. One report described a Georgia woman participating in litigation claiming a link between GLP-1 weight loss drugs and blindness. Legal commentary has also discussed similar claims involving liraglutide products such as Saxenda.&lt;/p&gt;
&lt;p&gt;These are allegations. No court has determined that any GLP-1 medication causes NAION, and the manufacturers dispute the claims. What follows is an explanation of the condition, what the published research actually reports, and what people who have experienced sudden vision loss should understand.&lt;/p&gt;
&lt;p&gt;NAION stands for non-arteritic anterior ischemic optic neuropathy. It is an injury to the optic nerve (the bundle of fibers that carries visual signals from the eye to the brain) caused by an interruption in blood supply to the front portion of that nerve.&lt;/p&gt;</content:encoded></item><item><title>Beyond CRE: VRE and Other Superbug Claims After ERCP</title><link>https://nulegal.com/blog/beyond-cre-vre-and-other-superbug-claims-after-ercp/</link><guid isPermaLink="true">https://nulegal.com/blog/beyond-cre-vre-and-other-superbug-claims-after-ercp/</guid><description>A newly reported Olympus lawsuit alleges a fatal VRE infection following ERCP, a reminder that duodenoscope infection claims are not limited to carbapenem-resistant organisms. Here is what these individually filed cases allege and what records matter.</description><pubDate>Sun, 02 Aug 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Most of the public conversation about contaminated endoscopes has centered on CRE: carbapenem-resistant Enterobacterales, the organism involved in the hospital outbreaks that first drew national attention years ago. That focus is understandable, but it has left many families with the wrong impression: that unless the culture report said &amp;quot;CRE,&amp;quot; there is nothing to look at.&lt;/p&gt;
&lt;p&gt;Industry press has recently reported a new lawsuit against Olympus alleging that a patient contracted a fatal VRE infection (vancomycin-resistant Enterococcus) after an ERCP performed with a reusable duodenoscope. The allegations in that filing have not been tested in court, and nothing about the case has been proven. But the reporting is a useful correction to a common assumption. The organisms named in these claims have included Pseudomonas, E. coli, Klebsiella, and enterococci, not CRE alone.&lt;/p&gt;
&lt;p&gt;If you or a relative developed a serious infection after an endoscopic procedure, the name of the bacterium is not a threshold question you have to answer before anyone will look at the file.&lt;/p&gt;</content:encoded></item><item><title>Failure to Warn: What Dupixent Lymphoma Lawsuits Allege</title><link>https://nulegal.com/blog/failure-to-warn-what-dupixent-lymphoma-lawsuits-allege/</link><guid isPermaLink="true">https://nulegal.com/blog/failure-to-warn-what-dupixent-lymphoma-lawsuits-allege/</guid><description>Dupixent lawsuits center on a failure-to-warn theory: that patients and prescribing doctors were not told about a possible cutaneous T-cell lymphoma risk. Here is what those allegations say, and what remains unproven.</description><pubDate>Sun, 02 Aug 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you have read anything about the Dupixent (dupilumab) lawsuits, you have probably seen the phrase failure to warn. Reported filings, described in coverage from outlets such as AboutLawsuits.com and LawyersandSettlements.com, allege that Sanofi and Regeneron did not adequately warn patients or prescribing physicians about a possible association between Dupixent and cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome.&lt;/p&gt;
&lt;p&gt;That is a specific legal theory, not a general statement that the drug is harmful. Understanding the difference matters, because it shapes what a claim has to show, what records matter, and who might have a claim at all.&lt;/p&gt;
&lt;p&gt;This litigation is early. Very little has been established as fact. Everything below is described as an allegation under examination or as general medical background, and none of it should be read as a finding that Dupixent causes cancer.&lt;/p&gt;
&lt;p&gt;Under product liability law in most states, a manufacturer can be held responsible not only for how a product is made, but for what it tells people about the product&apos;s risks. A failure-to-warn claim generally alleges that:&lt;/p&gt;</content:encoded></item><item><title>Section 230 and Design Claims in Social Media Addiction Cases</title><link>https://nulegal.com/blog/section-230-and-design-claims-in-social-media-addiction-cases/</link><guid isPermaLink="true">https://nulegal.com/blog/section-230-and-design-claims-in-social-media-addiction-cases/</guid><description>Courts handling adolescent social media addiction claims have drawn a line between suing over content and suing over platform design. Here is what that distinction means for parents weighing a claim on behalf of a teen.</description><pubDate>Sun, 02 Aug 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you have read anything about the social media addiction lawsuits filed against Meta, TikTok, Snap, and YouTube, you have probably run into a confusing pattern: some claims move forward toward trial, while others are dismissed early, sometimes in the very same case, brought by the very same family.&lt;/p&gt;
&lt;p&gt;That is not random. It reflects a legal line that judges in these cases have been drawing for several years now, and it is one of the most important things a parent can understand before deciding whether to pursue a claim.&lt;/p&gt;
&lt;p&gt;The short version: courts have generally been far more receptive to allegations about how a platform is built than to allegations about what other users posted on it. Understanding why helps explain what these cases are actually about, and what kind of information matters most if you are considering one.&lt;/p&gt;
&lt;p&gt;Section 230 of the Communications Decency Act is a federal statute that, in broad terms, says an online service generally cannot be treated as the publisher or speaker of information provided by someone else. You can read the statutory text itself through the Legal Information Institute at Cornell Law School.&lt;/p&gt;</content:encoded></item><item><title>Why PowerPort Juries Won&apos;t Hear About Bard&apos;s IVC Filters</title><link>https://nulegal.com/blog/why-powerport-juries-wont-hear-about-bards-ivc-filters/</link><guid isPermaLink="true">https://nulegal.com/blog/why-powerport-juries-wont-hear-about-bards-ivc-filters/</guid><description>Legal trade press has reported that the judge overseeing the Bard PowerPort litigation limited evidence about Bard&apos;s separate IVC filter problems. Here is what that kind of evidentiary ruling means, and what juries in port catheter cases actually hear.</description><pubDate>Sun, 02 Aug 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you have been following the Bard PowerPort litigation, you have probably read about the trials themselves: the first bellwether, the verdict, the trial scheduled to follow it. What gets far less attention are the pretrial rulings that decide what a jury is allowed to hear before anyone gives an opening statement.&lt;/p&gt;
&lt;p&gt;One of those rulings has been reported by legal trade press: the court overseeing the coordinated PowerPort proceedings reportedly limited what juries can be told about problems with a different Bard product line, its inferior vena cava (IVC) filters. To someone living with a fractured or infected port, that can sound like the deck is being stacked. It usually is not. Understanding why courts draw these lines is one of the more useful things a person considering a claim can learn, because it explains what a case actually has to prove.&lt;/p&gt;
&lt;p&gt;This post is general information, not legal or medical advice about your situation.&lt;/p&gt;
&lt;p&gt;The Bard PowerPort is an implanted port catheter (a small reservoir placed under the skin, connected to a catheter threaded into a large vein) used to deliver chemotherapy, antibiotics, nutrition, contrast dye, and other treatments without repeated needle sticks. For many patients in cancer treatment, it is what makes months of infusions tolerable.&lt;/p&gt;</content:encoded></item><item><title>NAION Vision Loss Claims Move to Center of GLP-1 Litigation</title><link>https://nulegal.com/blog/naion-vision-loss-claims-move-to-center-of-glp-1-litigation/</link><guid isPermaLink="true">https://nulegal.com/blog/naion-vision-loss-claims-move-to-center-of-glp-1-litigation/</guid><description>Reports indicate that early discovery in GLP-1 vision loss lawsuits is focusing on NAION, a form of sudden optic nerve injury. Here is what patients and families should understand about the condition, the research, and the litigation.</description><pubDate>Wed, 29 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Most early coverage of GLP-1 medication litigation focused on the digestive system: gastroparesis, bowel obstruction, gallbladder complications, and pancreatitis. More recently, a separate category of claim has drawn attention: sudden, often permanent vision loss in one or both eyes.&lt;/p&gt;
&lt;p&gt;According to reporting from AboutLawsuits.com and other litigation trackers, the alleged link between GLP-1 medications and a condition called NAION is expected to be a focus of early discovery in these vision loss cases. Local outlets, including a WSB-TV report on a Georgia woman participating in such a claim, have described plaintiffs alleging that they lost vision after using GLP-1 drugs.&lt;/p&gt;
&lt;p&gt;This post explains what NAION is, what the published research does and does not establish, and how the litigation process typically handles a newer injury theory like this one.&lt;/p&gt;
&lt;p&gt;NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain terms, it involves a loss of adequate blood flow to the front portion of the optic nerve, the bundle of fibers that carries visual signals from the eye to the brain.&lt;/p&gt;</content:encoded></item><item><title>Dupixent CTCL Cases Centralized: What MDL Consolidation Means</title><link>https://nulegal.com/blog/dupixent-ctcl-cases-centralized-what-mdl-consolidation-means/</link><guid isPermaLink="true">https://nulegal.com/blog/dupixent-ctcl-cases-centralized-what-mdl-consolidation-means/</guid><description>Federal Dupixent lymphoma lawsuits have been centralized into a single multidistrict litigation. Here is what that procedural step means for people diagnosed with cutaneous T-cell lymphoma, and what it does not decide.</description><pubDate>Sun, 26 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Legal trade coverage has reported that federal lawsuits alleging a connection between Dupixent (dupilumab) and cutaneous T-cell lymphoma (CTCL) have been consolidated into a single multidistrict litigation: MDL 3180, assigned to the District of New Jersey. Reports indicate the Judicial Panel on Multidistrict Litigation took that step in mid-2026, after plaintiffs sought centralization of cases that had been filed in different federal districts.&lt;/p&gt;
&lt;p&gt;If you or someone in your family was treated with Dupixent for eczema or atopic dermatitis and later received a CTCL diagnosis, you may have seen headlines describing this as a major development. It is a real one, but it is a procedural development, and understanding exactly what it changed is more useful than the headline itself.&lt;/p&gt;
&lt;p&gt;When similar lawsuits are filed in courts around the federal system, the JPML can transfer them to one district judge for coordinated pretrial handling. That judge then manages the shared work: document production from the defendants, expert disclosures, scheduling, and disputes over what evidence is admissible.&lt;/p&gt;</content:encoded></item><item><title>Port Catheter Infection and Sepsis Claims: What Patients Should Know</title><link>https://nulegal.com/blog/port-catheter-infection-and-sepsis-claims-what-patients-should-know/</link><guid isPermaLink="true">https://nulegal.com/blog/port-catheter-infection-and-sepsis-claims-what-patients-should-know/</guid><description>An overview of the bloodstream infection and sepsis allegations in the Bard PowerPort litigation, including how catheter-related infections are diagnosed and which medical records tend to matter most.</description><pubDate>Sun, 26 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;An implanted port is a small device placed under the skin of the chest or upper arm and connected to a thin catheter that threads into a large vein. It gives clinicians repeated, reliable access to the bloodstream without sticking a new peripheral IV each visit.&lt;/p&gt;
&lt;p&gt;For people going through chemotherapy, long courses of antibiotics, dialysis support, or frequent contrast imaging, a port can be the difference between a tolerable treatment schedule and a miserable one. The National Cancer Institute describes central venous access devices as a routine part of modern cancer care.&lt;/p&gt;
&lt;p&gt;That context matters. Most people who received a Bard PowerPort or a similar device were already seriously ill. They accepted the device because their care team recommended it, and they had no realistic way to evaluate one manufacturer&apos;s design against another&apos;s.&lt;/p&gt;
&lt;p&gt;Lawsuits filed over the Bard PowerPort are consolidated in federal multidistrict litigation, and they raise several categories of alleged injury. One of those categories involves bloodstream infection and sepsis said to have followed placement of the device.&lt;/p&gt;</content:encoded></item><item><title>Preserving Roblox Chat Logs and Account Records for a Claim</title><link>https://nulegal.com/blog/preserving-roblox-chat-logs-and-account-records-for-a-claim/</link><guid isPermaLink="true">https://nulegal.com/blog/preserving-roblox-chat-logs-and-account-records-for-a-claim/</guid><description>A practical guide for parents and guardians on saving Roblox chat history, account data, Robux purchase records, and related documentation while child safety litigation against Roblox Corporation moves forward. Includes what to do first if a child is in danger.</description><pubDate>Sun, 26 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Roblox child safety claims are, at their core, claims about what happened inside a product. The allegations plaintiffs have raised concern chat and messaging features, private servers, age-verification and moderation practices, features that encourage extended play, and in-game purchases made without a parent&apos;s knowledge. All of those live in digital records, not in a police report, and usually not in anything a family printed out at the time.&lt;/p&gt;
&lt;p&gt;That creates a practical problem. Parents often discover a problem weeks or months after it began, and their first instinct is understandable: delete the account, wipe the device, and make it go away. That instinct protects a child emotionally in the short term, but it can permanently remove the records that would later document what happened.&lt;/p&gt;
&lt;p&gt;This post walks through what is worth preserving, what to do first if a child may still be in contact with someone dangerous, and what you do not need to have in order to speak with a lawyer. Nothing here requires you to investigate anything yourself, and none of it requires your child to retell what happened.&lt;/p&gt;</content:encoded></item><item><title>Reusable Duodenoscopes and the Push Toward Disposable Designs</title><link>https://nulegal.com/blog/reusable-duodenoscopes-and-the-push-toward-disposable-designs/</link><guid isPermaLink="true">https://nulegal.com/blog/reusable-duodenoscopes-and-the-push-toward-disposable-designs/</guid><description>A newly reported lawsuit alleges a fatal infection after an ERCP performed with a reusable duodenoscope. Here is what the reported FDA transition toward disposable designs involves, and how these individually filed claims work.</description><pubDate>Sun, 26 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Industry press has reported a newly filed lawsuit against Olympus alleging that a patient contracted vancomycin-resistant Enterococcus (VRE) after a procedure performed with a reusable duodenoscope, and that the infection was fatal. Other reported filings describe sepsis and death following endoscopic retrograde cholangiopancreatography (ERCP).&lt;/p&gt;
&lt;p&gt;These are allegations. No court has determined that any manufacturer caused any of these infections, and the companies dispute the claims. But the filings raise a question that patients and families have every reason to ask: after years of revised cleaning instructions, recalls, and design changes, can a reusable duodenoscope still carry organisms from one patient to the next?&lt;/p&gt;
&lt;p&gt;That question is what this post is about, and what people who developed a drug-resistant infection after an ERCP are often trying to understand before they talk to anyone about a claim.&lt;/p&gt;
&lt;p&gt;A duodenoscope is a flexible, camera-tipped instrument threaded through the mouth, stomach, and into the small intestine so a physician can reach the bile and pancreatic ducts. ERCP is the main procedure that uses it, and for many patients with gallstones blocking a duct, bile duct strictures, or pancreatic disease, it is the least invasive option available.&lt;/p&gt;</content:encoded></item><item><title>When One Platform Settles: What Parents Should Understand</title><link>https://nulegal.com/blog/when-one-platform-settles-what-parents-should-understand/</link><guid isPermaLink="true">https://nulegal.com/blog/when-one-platform-settles-what-parents-should-understand/</guid><description>Reports of settlements by individual social media companies and appeals of early verdicts have raised questions for families with pending claims. Here is what a partial settlement does and does not mean for a minor&apos;s case.</description><pubDate>Sun, 26 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you are the parent or guardian of a teenager with a pending social media addiction claim, the last several months have probably been confusing to follow. Litigation reporting has described early trial verdicts, an appeal by Meta, a reported settlement by TikTok in a case set for trial, and a reported settlement between Google and a school district plaintiff.&lt;/p&gt;
&lt;p&gt;Each of those headlines describes something real, but none of them describes the same thing. They involve different defendants, different plaintiffs, and different kinds of claims. A settlement by one company in one case is not a resolution of the litigation, and it is not a ruling about what happened to your child.&lt;/p&gt;
&lt;p&gt;This post walks through what these developments generally mean (and, just as importantly, what they do not mean) for a family whose case is still pending.&lt;/p&gt;
&lt;p&gt;This is the single most important point, and it cuts in both directions.&lt;/p&gt;
&lt;p&gt;When a defendant settles a case before trial, the settlement is almost always accompanied by an express denial of liability. Companies settle for many reasons that have nothing to do with conceding a claim: to remove uncertainty, to avoid the cost and disruption of trial, to keep internal documents and testimony out of a public courtroom, or because a particular case has facts they would rather not put in front of a jury.&lt;/p&gt;</content:encoded></item><item><title>NAION Vision Loss Claims and GLP-1 Litigation Explained</title><link>https://nulegal.com/blog/naion-vision-loss-claims-and-glp-1-litigation-explained/</link><guid isPermaLink="true">https://nulegal.com/blog/naion-vision-loss-claims-and-glp-1-litigation-explained/</guid><description>An overview of NAION, the reported association between GLP-1 medications and sudden vision loss, and how those allegations are being raised in ongoing litigation. Educational information for patients researching their own eye injury.</description><pubDate>Wed, 22 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Medications in the GLP-1 receptor agonist class, including semaglutide (marketed as Ozempic, Wegovy, and Rybelsus), tirzepatide (Mounjaro), and liraglutide (Saxenda, Victoza), have become some of the most widely discussed prescription drugs of the past several years. Most of the early litigation reporting focused on gastrointestinal complaints such as gastroparesis, bowel obstruction, and gallbladder disease.&lt;/p&gt;
&lt;p&gt;More recently, legal reporting has described a different category of claim: sudden, permanent vision loss in one eye, attributed by plaintiffs to a condition called NAION. Legal industry coverage has indicated that the reported connection between NAION and semaglutide products is expected to be an early focus of discovery in GLP-1 vision loss cases.&lt;/p&gt;
&lt;p&gt;If you or someone you love woke up with unexplained vision loss while taking one of these medications, this article is meant to help you understand the condition, what the research does and does not say, and how these claims are being framed in court.&lt;/p&gt;</content:encoded></item><item><title>After the First Trials: What Comes Next for Pending Teen Claims</title><link>https://nulegal.com/blog/after-the-first-trials-what-comes-next-for-pending-teen-claims/</link><guid isPermaLink="true">https://nulegal.com/blog/after-the-first-trials-what-comes-next-for-pending-teen-claims/</guid><description>Reported verdicts and a settlement in the first social media addiction cases have changed the landscape for families with pending claims. Here is what bellwether trials actually decide, and what they do not, for your child&apos;s case.</description><pubDate>Sun, 19 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you are the parent or guardian of a teenager whose claim is part of the social media addiction litigation, you have probably seen the headlines. Reports have described the first trial against major platforms getting underway, a verdict returned against Meta and YouTube, and at least one defendant (TikTok) reportedly resolving a case before it reached a jury. Coverage has also described a school district resolving claims with Google.&lt;/p&gt;
&lt;p&gt;Those are real developments, and they matter. But they are also easy to misread. A verdict in one family&apos;s case is not a ruling about your child&apos;s case, and a settlement by one defendant does not mean every defendant will follow. This post walks through what actually happened, what a bellwether trial decides, and what a family with a pending claim should reasonably expect next.&lt;/p&gt;
&lt;p&gt;If you are new to this litigation, our social media addiction practice page covers the basics of who is being sued and on what theories.&lt;/p&gt;
&lt;p&gt;The claims consolidated in the federal multidistrict litigation and the parallel California state court proceeding are brought against Meta (Instagram and Facebook), TikTok, Snap, and YouTube. They are not ordinary content lawsuits. Plaintiffs allege that the platforms were designed to maximize the time adolescent users spend on them (through features like infinite scroll, autoplay, variable-reward notification systems, appearance-altering filters, and engagement-optimized recommendation feeds) and that the companies knew or should have known those design choices carried risk for developing adolescent brains.&lt;/p&gt;</content:encoded></item><item><title>Mycosis Fungoides, Sézary Syndrome, and Dupixent Claims Explained</title><link>https://nulegal.com/blog/mycosis-fungoides-szary-syndrome-and-dupixent-claims-explained/</link><guid isPermaLink="true">https://nulegal.com/blog/mycosis-fungoides-szary-syndrome-and-dupixent-claims-explained/</guid><description>A plain-language look at cutaneous T-cell lymphoma, why mycosis fungoides is often mistaken for eczema, and the two theories plaintiffs have raised in the Dupixent CTCL litigation.</description><pubDate>Sun, 19 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you or someone in your family was treated with Dupixent (dupilumab) for eczema or atopic dermatitis and later received a diagnosis of cutaneous T-cell lymphoma, you have probably heard two unfamiliar terms from your dermatologist or oncologist: mycosis fungoides and Sézary syndrome.&lt;/p&gt;
&lt;p&gt;Those two names appear repeatedly in the lawsuits that have been filed against Sanofi and Regeneron. Reported filings include claims such as one described by AboutLawsuits.com alleging that a Dupixent user was later diagnosed with mycosis fungoides.&lt;/p&gt;
&lt;p&gt;This post explains what those diagnoses are, why they are so easily confused with severe eczema, and how they relate to the claims plaintiffs have begun bringing. It is educational. Nothing here is a statement that Dupixent has been proven to cause cancer. That question is disputed and is exactly what the litigation is examining.&lt;/p&gt;
&lt;p&gt;Cutaneous T-cell lymphoma, usually shortened to CTCL, is a group of rare cancers of a type of white blood cell called a T lymphocyte. Unlike most lymphomas, which are first found in lymph nodes, CTCL first shows up in the skin.&lt;/p&gt;</content:encoded></item><item><title>Roblox Safety Updates: What They Mean for Your Family&apos;s Claim</title><link>https://nulegal.com/blog/roblox-safety-updates-what-they-mean-for-your-familys-claim/</link><guid isPermaLink="true">https://nulegal.com/blog/roblox-safety-updates-what-they-mean-for-your-familys-claim/</guid><description>Roblox has publicized new age-check and parental-control measures while facing child safety lawsuits and regulatory scrutiny. Here is what those changes mean for parents considering a claim, and what records to preserve.</description><pubDate>Sun, 19 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Roblox has publicly said it continues to push toward stronger digital safety standards, and news coverage has described new age-check and parental-control measures on the platform. At the same time, state attorneys general have filed lawsuits, child safety organizations have reportedly urged the Federal Trade Commission to investigate, and individual families have begun filing their own claims.&lt;/p&gt;
&lt;p&gt;Parents who read both sets of headlines often land in the same place: if the platform is fixing things now, does that mean it is too late (or too early) to do anything about what already happened to my child?&lt;/p&gt;
&lt;p&gt;This post walks through what the lawsuits allege, how a family&apos;s private claim differs from a state enforcement action, and what to preserve before account records disappear. Nothing here is a prediction about any outcome. These cases are active, the allegations are unproven, and Roblox Corporation has denied wrongdoing.&lt;/p&gt;
&lt;p&gt;The claims that have been reported publicly cluster around a handful of themes:&lt;/p&gt;</content:encoded></item><item><title>The Next Bard PowerPort Bellwether: Fracture Claims Take Center Stage</title><link>https://nulegal.com/blog/the-next-bard-powerport-bellwether-fracture-claims-take-center-stage/</link><guid isPermaLink="true">https://nulegal.com/blog/the-next-bard-powerport-bellwether-fracture-claims-take-center-stage/</guid><description>The first Bard PowerPort bellwether trial ended in a defense verdict on infection allegations. Reports indicate the next trial focuses on catheter fracture and migration: here is what that difference means for patients following the litigation.</description><pubDate>Sun, 19 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you have been following the Bard PowerPort litigation, you may have seen headlines about the first bellwether trial ending in a defense verdict for C.R. Bard. That result was widely reported, and understandably it left a lot of patients wondering whether their own claim still matters.&lt;/p&gt;
&lt;p&gt;It does, and one reason is that the reported second bellwether trial, set for August 2026, is not a repeat of the first. According to litigation reporting, that trial involves catheter fracture allegations rather than the infection allegations a jury heard the first time around. Those are different injuries, supported by different records, and argued with different evidence.&lt;/p&gt;
&lt;p&gt;This post explains what that distinction means, in plain language, for people living with a port catheter injury.&lt;/p&gt;
&lt;p&gt;An implanted port is a small device placed under the skin, usually in the chest, connected to a thin flexible tube (the catheter) that threads into a large vein. It gives clinicians reliable long-term access to the bloodstream without repeated needle sticks in the arm.&lt;/p&gt;</content:encoded></item><item><title>Why the Duodenoscope Elevator Mechanism Drives Infection Lawsuits</title><link>https://nulegal.com/blog/why-the-duodenoscope-elevator-mechanism-drives-infection-lawsuits/</link><guid isPermaLink="true">https://nulegal.com/blog/why-the-duodenoscope-elevator-mechanism-drives-infection-lawsuits/</guid><description>Lawsuits over infections after ERCP focus on the duodenoscope&apos;s reusable elevator mechanism and its cleaning instructions. Here is what those allegations claim, what the FDA has said, and how these individually filed claims work.</description><pubDate>Sun, 19 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you or a family member developed a serious infection after an ERCP or another procedure using a flexible endoscope, you may have seen news coverage mentioning the scope&apos;s elevator mechanism. It is a small, hinged part at the tip of a duodenoscope, and it has become the focus of much of the litigation now being brought against scope manufacturers including Olympus, Fujifilm and Pentax.&lt;/p&gt;
&lt;p&gt;This post explains what that part does, what plaintiffs allege about it, and what the FDA has publicly said about duodenoscope-associated infections. It is educational only. Nothing here predicts an outcome in any case, and none of the allegations described below has been established as fact.&lt;/p&gt;
&lt;p&gt;ERCP stands for endoscopic retrograde cholangiopancreatography. A physician passes a flexible scope through the mouth and stomach into the upper small intestine to reach the bile and pancreatic ducts. It is used to remove gallstones, relieve blockages, place stents, and take tissue samples. The National Institute of Diabetes and Digestive and Kidney Diseases publishes patient-facing background on ERCP and related digestive procedures.&lt;/p&gt;</content:encoded></item><item><title>Depo-Provera Meningioma Updates for Patients</title><link>https://nulegal.com/blog/depo-provera-meningioma-updates-for-patients/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-meningioma-updates-for-patients/</guid><description>Recent Depo-Provera headlines have focused on meningioma warnings, medical studies, and active litigation. This guide explains what patients should understand without overstating what courts or studies have decided.</description><pubDate>Wed, 15 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Recent headlines have renewed attention on Depo-Provera and meningioma claims.&lt;/p&gt;
&lt;p&gt;Many patients are trying to understand whether a past contraceptive shot could relate to a later brain tumor diagnosis.&lt;/p&gt;
&lt;p&gt;The current public discussion includes medical studies, reported label-warning developments, and active product-liability litigation.&lt;/p&gt;
&lt;p&gt;Those are separate issues, and each should be understood carefully.&lt;/p&gt;
&lt;p&gt;A study can report an association without proving causation.&lt;/p&gt;</content:encoded></item><item><title>After the First PowerPort Bellwether Verdict: What Comes Next</title><link>https://nulegal.com/blog/after-the-first-powerport-bellwether-verdict-what-comes-next/</link><guid isPermaLink="true">https://nulegal.com/blog/after-the-first-powerport-bellwether-verdict-what-comes-next/</guid><description>A jury returned a defense verdict in the first Bard PowerPort bellwether trial over infection claims, and a second bellwether focused on catheter fracture has been reported as next. Here is what those trials decide, what they do not, and what it means for people with implanted port claims.</description><pubDate>Sun, 12 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you have an implanted port claim, you may have seen headlines reporting that a jury returned a defense verdict in the first Bard PowerPort bellwether trial, meaning the jury did not find for the plaintiff in that case. Legal news outlets have also reported that plaintiff&apos;s counsel sought a new trial following that verdict.&lt;/p&gt;
&lt;p&gt;That is discouraging news, and it would be dishonest to describe it any other way. But a single trial result is not the end of the litigation, and it is not a ruling about your case. Understanding exactly what that jury decided, and what it had no power to decide, is the difference between reading a headline and understanding where things actually stand.&lt;/p&gt;
&lt;p&gt;When many similar lawsuits are consolidated for pretrial handling in federal court, the court does not try them all. Instead, a small number of representative cases are selected as bellwether trials: test cases meant to show both sides how juries respond to the evidence, the witnesses, and the theories being argued.&lt;/p&gt;</content:encoded></item><item><title>Diagnosed Before Dupixent? The Masking Claim Explained</title><link>https://nulegal.com/blog/diagnosed-before-dupixent-the-masking-claim-explained/</link><guid isPermaLink="true">https://nulegal.com/blog/diagnosed-before-dupixent-the-masking-claim-explained/</guid><description>Dupixent CTCL lawsuits plead two separate theories: that the drug may cause or accelerate cutaneous T-cell lymphoma, and that it may mask early lymphoma symptoms and delay diagnosis. Here is what that second theory means for patients diagnosed before, during, or after treatment.</description><pubDate>Sun, 12 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Most coverage of the Dupixent (dupilumab) litigation describes it in a single sentence: patients treated for eczema or atopic dermatitis were later diagnosed with cutaneous T-cell lymphoma (CTCL), and they have sued Sanofi and Regeneron. That summary is accurate as far as it goes, but it leaves out half of what the filed cases actually plead.&lt;/p&gt;
&lt;p&gt;The lawsuits that have been reported so far advance two distinct theories, and they are not the same claim:&lt;/p&gt;
&lt;p&gt;Both remain allegations under examination. Neither has been established as a proven biological mechanism, and no court has found that Dupixent causes cancer. But the difference between the two matters enormously to individual patients, because the second theory changes who might have a claim at all.&lt;/p&gt;
&lt;p&gt;This post explains the masking limb in plain language: what it alleges, why it exists, and why a patient who says &amp;quot;but my lymphoma was diagnosed before I ever started Dupixent&amp;quot; should not assume the answer is no.&lt;/p&gt;
&lt;p&gt;Cutaneous T-cell lymphoma is a group of rare cancers in which certain white blood cells called T-cells become malignant and collect in the skin. The most common form is mycosis fungoides. A more aggressive, blood-involved variant is Sézary syndrome.&lt;/p&gt;</content:encoded></item><item><title>Endoscope Infection Claims Are Filed Individually, Not Consolidated</title><link>https://nulegal.com/blog/endoscope-infection-claims-are-filed-individually-not-consolidated/</link><guid isPermaLink="true">https://nulegal.com/blog/endoscope-infection-claims-are-filed-individually-not-consolidated/</guid><description>Duodenoscope and endoscope infection lawsuits against Olympus, Fujifilm and Pentax are pursued as individual cases in state and federal courts, not through an MDL or class action. Here is what that means for patients and families.</description><pubDate>Sun, 12 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you have read anything about Depo-Provera, Ozempic, or Bard PowerPort litigation, you have read about MDLs: federal cases pooled before one judge, with bellwether trials and coordinated discovery. Contaminated endoscope infection claims work differently.&lt;/p&gt;
&lt;p&gt;There is no MDL and no class action for endoscope and duodenoscope infection claims. They are filed individually, one patient or family at a time, in state and federal courts. Some lawsuits against scope manufacturers have been reported publicly, including cases described in industry coverage as involving infection and sepsis after ERCP procedures. But there is no consolidated proceeding gathering them, no master docket, and no single judge managing them together.&lt;/p&gt;
&lt;p&gt;That is not a technicality. It changes almost everything about how a case is built, where it is filed, and how long it takes.&lt;/p&gt;
&lt;p&gt;The reported cases generally involve patients who underwent ERCP (endoscopic retrograde cholangiopancreatography) or another procedure using a reusable flexible scope, and who then developed a serious infection, including drug-resistant organisms such as CRE and other carbapenem-resistant bacteria, Pseudomonas, E. coli, Klebsiella, and, in at least one lawsuit reported by trade press, vancomycin-resistant enterococcus. Some patients developed sepsis. Some died.&lt;/p&gt;</content:encoded></item><item><title>First Social Media Addiction Verdicts: What Parents Should Know</title><link>https://nulegal.com/blog/first-social-media-addiction-verdicts-what-parents-should-know/</link><guid isPermaLink="true">https://nulegal.com/blog/first-social-media-addiction-verdicts-what-parents-should-know/</guid><description>Reported verdicts against Meta and YouTube, plus settlements by TikTok and Google ahead of trial, have moved social media addiction litigation into a new phase. Here is what those developments do and do not mean for a parent considering a claim.</description><pubDate>Sun, 12 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;For several years, claims that social media platforms were designed to keep adolescents engaged in ways that harmed their mental health existed mostly on paper: complaints, motions, and pretrial rulings. That changed when the first of these cases actually reached a jury.&lt;/p&gt;
&lt;p&gt;According to reports from legal trade press, a landmark trial against Meta and YouTube ended in a multimillion-dollar verdict for the plaintiff, and separately, TikTok has been reported to have settled a social media addiction case ahead of a scheduled trial. Google has also been reported to have reached a resolution with a school district plaintiff, while Meta has been reported to be appealing the verdict against it.&lt;/p&gt;
&lt;p&gt;If you are a parent or guardian trying to figure out what any of this means for your own child, this post walks through what has actually happened, what remains unresolved, and what a family in this situation can realistically do next. Nothing here is a prediction about any individual case.&lt;/p&gt;
&lt;p&gt;The lawsuits consolidated in federal multidistrict litigation (commonly referred to as MDL 3047) and in a parallel California state court proceeding bring two broad categories of claims against Meta/Instagram, TikTok, Snapchat, and YouTube:&lt;/p&gt;</content:encoded></item><item><title>State Roblox Lawsuits and Your Family&apos;s Own Claim</title><link>https://nulegal.com/blog/state-roblox-lawsuits-and-your-familys-own-claim/</link><guid isPermaLink="true">https://nulegal.com/blog/state-roblox-lawsuits-and-your-familys-own-claim/</guid><description>State attorneys general have sued Roblox over child safety, and some have reached reported settlements. Here is what those government actions do and do not do for your family, and how private claims are being pursued.</description><pubDate>Sun, 12 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you have a child who plays Roblox, you have probably noticed a steady stream of headlines over the past several months. News outlets have reported that attorneys general in states including Arkansas, Oklahoma, Nebraska, and Indiana have filed lawsuits against Roblox Corporation over child safety, that Connecticut opened an investigation, and that Roblox reached settlements with Alabama and West Virginia (reported by Reuters at a combined $23 million), resolving those states&apos; child safety investigations. Child safety organizations have also publicly urged the Federal Trade Commission to look at the platform&apos;s practices.&lt;/p&gt;
&lt;p&gt;That is a lot of activity, and it raises a reasonable question for parents: does any of this do anything for my child?&lt;/p&gt;
&lt;p&gt;The honest answer is that government enforcement and a private family claim are two different tracks. Understanding the difference is the most useful thing a parent can learn right now, because the headlines can easily create the impression that a settlement has already been reached on behalf of families. It has not.&lt;/p&gt;</content:encoded></item><item><title>Depo-Provera: FDA Adds Brain Tumor Warning to Label</title><link>https://nulegal.com/blog/depo-provera-fda-adds-brain-tumor-warning-to-label/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-fda-adds-brain-tumor-warning-to-label/</guid><description>Learn about the recent FDA label change for Depo-Provera, including a new warning about the potential risk of meningioma brain tumors. This update impacts users and ongoing litigation.</description><pubDate>Wed, 08 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;For many years, Depo-Provera has been a widely used contraceptive option for women. However, recent developments have brought critical safety information to light. In December 2025, the U.S. Food and Drug Administration (FDA) approved a significant update to the prescribing information for Depo-Provera, adding a warning that cases of meningioma, a type of brain tumor, have been reported following repeated use, primarily with long-term use. This FDA action follows growing medical research and numerous lawsuits alleging that the drug&apos;s manufacturer failed to adequately warn patients and healthcare providers about this serious risk.&lt;/p&gt;
&lt;p&gt;Depo-Provera contains medroxyprogesterone acetate (MPA), a synthetic form of the hormone progesterone, which works to prevent pregnancy. Meningiomas are typically slow-growing tumors that form on the meninges, the protective membranes surrounding the brain and spinal cord. While most meningiomas are benign (non-cancerous), their growth can lead to severe neurological symptoms depending on their size and location, sometimes requiring surgery or radiation.&lt;/p&gt;</content:encoded></item><item><title>GLP-1 Vision Loss Lawsuits: What You Need to Know</title><link>https://nulegal.com/blog/glp-1-vision-loss-lawsuits-what-you-need-to-know/</link><guid isPermaLink="true">https://nulegal.com/blog/glp-1-vision-loss-lawsuits-what-you-need-to-know/</guid><description>Explore the growing concerns and ongoing litigation surrounding GLP-1 medications like Ozempic and Wegovy, specifically addressing allegations of vision loss.</description><pubDate>Wed, 01 Jul 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Glucagon-like peptide-1 (GLP-1) receptor agonists, widely prescribed for type 2 diabetes and weight management, have garnered significant attention. Medications such as Ozempic, Wegovy, and Mounjaro have become increasingly popular, but reports of serious side effects are also emerging. Among these, allegations of vision loss, specifically a condition known as non-arteritic anterior ischemic optic neuropathy (NAION), have led to a rise in legal action against the manufacturers.&lt;/p&gt;
&lt;p&gt;NAION is a condition characterized by sudden damage to the optic nerve due to a lack of blood flow. This can result in a significant and often permanent loss of vision. While NAION can occur for various reasons, some patients taking GLP-1 agonists have reported experiencing this condition, leading to questions about a potential link.&lt;/p&gt;
&lt;p&gt;Recent headlines indicate a growing trend of lawsuits filed by individuals who allege they developed vision problems after using GLP-1 medications. These lawsuits often claim that the drug manufacturers failed to adequately warn patients and healthcare providers about the potential risk of NAION and other serious eye-related complications. The Judicial Panel on Multidistrict Litigation (JPML) is involved in consolidating these cases to streamline the legal process.&lt;/p&gt;</content:encoded></item><item><title>FDA Adds Meningioma Warning to Depo-Provera Label</title><link>https://nulegal.com/blog/fda-adds-meningioma-warning-to-depo-provera-label/</link><guid isPermaLink="true">https://nulegal.com/blog/fda-adds-meningioma-warning-to-depo-provera-label/</guid><description>The FDA-approved Depo-Provera label now addresses reported meningiomas after repeated use. Learn what the warning says, which symptoms warrant medical attention, and how the update may affect litigation.</description><pubDate>Wed, 24 Jun 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;The FDA-approved prescribing information for Depo-Provera now includes a warning concerning meningioma, a tumor arising from tissues surrounding the brain and spinal cord.&lt;/p&gt;
&lt;p&gt;The label states that meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use.&lt;/p&gt;
&lt;p&gt;It instructs healthcare professionals to monitor patients for signs and symptoms of meningioma and to discontinue Depo-Provera if a meningioma is diagnosed.&lt;/p&gt;
&lt;p&gt;The update also adds meningioma information to the patient-counseling section of the prescribing information.&lt;/p&gt;
&lt;p&gt;Patients can review general information about labeling and safety communications through the FDA drug safety section.&lt;/p&gt;</content:encoded></item><item><title>Depo-Provera: Understanding the New FDA Brain Tumor Warning</title><link>https://nulegal.com/blog/depo-provera-understanding-the-new-fda-brain-tumor-warning/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-understanding-the-new-fda-brain-tumor-warning/</guid><description>The FDA has reportedly updated the Depo-Provera label to include a warning about meningioma, a type of brain tumor. This post explores what this warning means for users and the status of related litigation.</description><pubDate>Wed, 17 Jun 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Depo-Provera, formally known as depot medroxyprogesterone acetate (DMPA), is a widely used injectable hormonal contraceptive. Administered every three months, it offers a convenient and effective method of birth control. Its mechanism involves preventing ovulation, thickening cervical mucus to block sperm, and thinning the uterine lining. While praised for its efficacy and ease of use, Depo-Provera, like all medications, comes with a profile of potential side effects and risks, necessitating continuous evaluation of its safety by regulatory bodies.&lt;/p&gt;
&lt;p&gt;In a significant development for public health and drug safety, the U.S. Food and Drug Administration (FDA) has reportedly approved a crucial label change for Depo-Provera. This update includes a new warning about meningioma, a type of brain tumor: cases of meningioma have been reported following repeated use of the drug, primarily with long-term use. This reported action by the FDA underscores a growing concern about the contraceptive and this serious health condition. A label change of this nature serves as an urgent alert to both healthcare providers and patients about potential adverse effects that may not have been fully understood or disclosed previously. Such updates are central to the FDA&apos;s mission to ensure the safety and effectiveness of medications available to the public. More information about the FDA&apos;s drug safety communications can be found on their official website FDA.&lt;/p&gt;</content:encoded></item><item><title>Depo-Provera and Meningioma: Understanding the Latest Lawsuit Information</title><link>https://nulegal.com/blog/depo-provera-and-meningioma-understanding-the-latest-lawsuit-information/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-and-meningioma-understanding-the-latest-lawsuit-information/</guid><description>Explore the emerging legal landscape surrounding Depo-Provera use and meningioma diagnoses. Learn about recent developments and what women should know.</description><pubDate>Fri, 12 Jun 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Recent discussions and legal actions highlight a growing concern: the potential link between the long-acting contraceptive injection, Depo-Provera, and the development of meningioma brain tumors. Women who have used Depo-Provera, particularly for extended periods, are increasingly seeking information about this association and their legal options. As litigation progresses, understanding these developments is crucial.&lt;/p&gt;
&lt;p&gt;A meningioma is a tumor that arises from the meninges, the membranes that surround the brain and spinal cord. These tumors are typically slow-growing and often benign, meaning they are not cancerous. However, even benign tumors can cause significant health problems if they grow large enough to press on the brain or spinal cord, leading to a range of neurological symptoms. Symptoms can vary widely but may include headaches, vision changes, seizures, and changes in personality or behavior.&lt;/p&gt;
&lt;p&gt;Research and legal filings suggest a potential association between the progestin component of Depo-Provera and an increased risk of meningioma. Some studies have explored how prolonged exposure to certain synthetic progestins, like those found in Depo-Provera, might influence the growth of hormone-sensitive tumors, including meningiomas. While research is ongoing, some reports indicate that women who used Depo-Provera for many years may have a higher risk of developing these brain tumors. It&apos;s important to note that medical research often establishes associations rather than definitive causation, and individual risk factors can vary.&lt;/p&gt;</content:encoded></item><item><title>Ozempic and GLP-1 Drugs: Understanding Gastroparesis and Bowel Obstruction Lawsuits</title><link>https://nulegal.com/blog/ozempic-and-glp-1-drugs-understanding-gastroparesis-and-bowel-obstruction-lawsui/</link><guid isPermaLink="true">https://nulegal.com/blog/ozempic-and-glp-1-drugs-understanding-gastroparesis-and-bowel-obstruction-lawsui/</guid><description>Explore the potential risks of GLP-1 medications like Ozempic and Wegovy, including gastroparesis and bowel obstruction, and understand the ongoing litigation addressing these serious side effects.</description><pubDate>Sun, 07 Jun 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly known by brand names such as Ozempic, Wegovy, Mounjaro, and Rybelsus, have become widely prescribed for managing type 2 diabetes and promoting weight loss. These medications work by mimicking a natural hormone to help regulate blood sugar and appetite. While they have shown significant benefits for many individuals, reports and ongoing litigation have raised concerns about severe gastrointestinal side effects associated with their use.&lt;/p&gt;
&lt;p&gt;Among the most concerning potential side effects linked to GLP-1 medications are gastroparesis and bowel obstruction. Gastroparesis, also known as stomach paralysis, is a condition where the stomach empties its contents too slowly, leading to a variety of uncomfortable and sometimes debilitating symptoms. These can include nausea, vomiting, early fullness when eating, abdominal pain, bloating, and significant fluctuations in blood sugar levels.&lt;/p&gt;
&lt;p&gt;Bowel obstruction, a blockage in the small or large intestine, is another serious complication that has been reported. This condition can prevent food or liquid from passing through the intestines and requires immediate medical attention. Symptoms can include severe abdominal pain, cramping, bloating, vomiting, and an inability to pass gas or have a bowel movement.&lt;/p&gt;</content:encoded></item><item><title>Depo-Provera Litigation Update: Meningioma Claims and Patient Awareness</title><link>https://nulegal.com/blog/depo-provera-litigation-update-meningioma-claims-and-patient-awareness/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-litigation-update-meningioma-claims-and-patient-awareness/</guid><description>Explore the latest in Depo-Provera litigation concerning meningioma brain tumors. Learn about the risks and what women who have used the drug should know.</description><pubDate>Wed, 03 Jun 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Depo-Provera, a widely used injectable contraceptive, has become the subject of significant legal scrutiny. Recent reports indicate a rising number of lawsuits alleging a link between the long-term use of Depo-Provera and the development of meningioma brain tumors. These lawsuits suggest that the progestin in Depo-Provera may contribute to the growth of these tumors, particularly with extended use over many years.&lt;/p&gt;
&lt;p&gt;The legal process for these claims is evolving, with court preparations for potential test trials and an increasing volume of filings being noted. Attorneys are reportedly reviewing cases where women developed meningiomas after using Depo-Provera, sometimes decades after their initial use of the birth control shots.&lt;/p&gt;
&lt;p&gt;While research continues to explore the complex relationship between hormonal contraceptives and brain tumors, regulatory bodies are also taking notice. Some reports suggest that the FDA has approved label changes for Depo-Provera, which may include new warnings or information regarding brain tumors. This evolving understanding underscores the importance of staying informed about potential drug risks.&lt;/p&gt;</content:encoded></item><item><title>FDA Depo-Provera Warning and Brain Tumor Lawsuits</title><link>https://nulegal.com/blog/fda-depo-provera-warning-and-brain-tumor-lawsuits/</link><guid isPermaLink="true">https://nulegal.com/blog/fda-depo-provera-warning-and-brain-tumor-lawsuits/</guid><description>Learn what the FDA’s updated Depo-Provera meningioma warning may mean for long-term users considering a brain tumor lawsuit in 2026. This guide explains the medical issue, litigation context, and records that may matter.</description><pubDate>Wed, 27 May 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;For many long-term Depo-Provera users, the new meningioma warning is not just a label update.&lt;/p&gt;
&lt;p&gt;It may be the first time they are seeing an official warning connected to a diagnosis that changed their life.&lt;/p&gt;
&lt;p&gt;Meningiomas are tumors that arise from the membranes around the brain and spinal cord, not from the brain tissue itself.&lt;/p&gt;
&lt;p&gt;Many are slow-growing and noncancerous, but benign does not mean harmless.&lt;/p&gt;
&lt;p&gt;A tumor can still press on nerves, vision pathways, blood vessels, or critical brain structures.&lt;/p&gt;</content:encoded></item><item><title>Depo-Provera Bellwether Trial Date and FDA Warning</title><link>https://nulegal.com/blog/depo-provera-bellwether-trial-date-and-fda-warning/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-bellwether-trial-date-and-fda-warning/</guid><description>Learn what the December 2026 Depo-Provera bellwether trial date may mean for women pursuing meningioma claims after the FDA added a brain tumor warning. This guide explains the litigation timeline, medical evidence, and practical next steps.</description><pubDate>Sun, 24 May 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;The first federal Depo-Provera bellwether trial is expected in December 2026, giving women with meningioma claims a clearer milestone in a litigation that has moved quickly.&lt;/p&gt;
&lt;p&gt;A bellwether trial is not a final settlement for everyone.&lt;/p&gt;
&lt;p&gt;It is an early trial chosen to test evidence, expert testimony, legal defenses, and how a jury responds to the core facts.&lt;/p&gt;
&lt;p&gt;For women who used Depo-Provera and later developed a meningioma, the date matters because it may shape settlement discussions, future trial scheduling, and the strength of negotiations across similar claims.&lt;/p&gt;
&lt;p&gt;It also comes after an important regulatory development: the FDA-approved labeling for Depo-Provera now includes a meningioma warning.&lt;/p&gt;</content:encoded></item><item><title>Wrongful Death from Compounded Semaglutide: Proving Contamination Claims</title><link>https://nulegal.com/blog/wrongful-death-from-compounded-semaglutide-proving-contamination-claims/</link><guid isPermaLink="true">https://nulegal.com/blog/wrongful-death-from-compounded-semaglutide-proving-contamination-claims/</guid><description>After April 2026 contamination reports, families pursuing wrongful death claims from compounded semaglutide face complex causation and liability questions. Learn what records to secure, how to prove pharmacy negligence, and whether federal or state court is your best path.</description><pubDate>Wed, 20 May 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Compounded semaglutide (unapproved, unregulated versions of the GLP-1 drug manufactured by pharmacies rather than pharmaceutical manufacturers) has emerged as a significant source of serious injuries and deaths. Unlike FDA-approved Ozempic or Wegovy, compounded versions lack standardized manufacturing controls, quality assurance, and sterility testing. When contamination occurs, families face a devastating reality: proving that pharmacy-compounded semaglutide, not the underlying medication itself, caused their loved one&apos;s death.&lt;/p&gt;
&lt;p&gt;Wrongful death claims from contaminated compounded drugs are winnable, but they require meticulous documentation and strategic litigation choices.&lt;/p&gt;
&lt;p&gt;To succeed in a wrongful death case stemming from contaminated compounded semaglutide, your legal team must establish four critical elements:&lt;/p&gt;
&lt;p&gt;Duty of Care. The pharmacy owed your family member a legal duty to compound semaglutide safely, to the same standard as an FDA-approved manufacturer. This includes proper sterilization, quality control, and honest labeling.&lt;/p&gt;</content:encoded></item><item><title>Federal Preemption After FDA Warning: What It Means for Meningioma Claims</title><link>https://nulegal.com/blog/federal-preemption-after-fda-warning-what-it-means-for-meningioma-claims/</link><guid isPermaLink="true">https://nulegal.com/blog/federal-preemption-after-fda-warning-what-it-means-for-meningioma-claims/</guid><description>The FDA&apos;s updated Depo-Provera meningioma warning significantly weakens Pfizer&apos;s federal preemption defense. Learn how the pending MDL ruling on preemption could reshape liability and valuations for women diagnosed in 2026.</description><pubDate>Wed, 13 May 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Federal preemption is a legal doctrine that shields pharmaceutical companies from state-law liability when the FDA has approved a drug and its labeling. The central argument: if the FDA approved this medication and approved this label, individual states cannot second-guess that federal decision through their own tort law. Preemption is rooted in the supremacy clause of the U.S. Constitution: federal law supersedes conflicting state law.&lt;/p&gt;
&lt;p&gt;For over a decade, Pfizer relied on federal preemption to dismiss many Depo-Provera meningioma claims before trial. The company argued it had complied with everything the FDA required. But the FDA&apos;s recent label change has fundamentally altered this landscape.&lt;/p&gt;
&lt;p&gt;In December 2025, the FDA updated Depo-Provera&apos;s prescribing information to include prominent warnings about meningioma risk, particularly among long-term users. This wasn&apos;t a routine clarification or minor note buried in small print. It warned that cases of meningioma have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use.&lt;/p&gt;</content:encoded></item><item><title>NAION and GLP-1 Drugs: What Vision Loss Claims Involve</title><link>https://nulegal.com/blog/naion-and-glp-1-drugs-what-vision-loss-claims-involve/</link><guid isPermaLink="true">https://nulegal.com/blog/naion-and-glp-1-drugs-what-vision-loss-claims-involve/</guid><description>An educational look at NAION, the sudden vision loss condition now at the center of GLP-1 injury lawsuits involving Ozempic, Wegovy, and Saxenda, and what the reported research and early litigation activity actually say.</description><pubDate>Wed, 06 May 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Most of the early public conversation about GLP-1 medications and injury focused on the digestive system: gastroparesis, bowel obstruction, gallbladder disease, and pancreatitis. More recently, a separate category of claim has drawn attention: sudden, painless vision loss in one eye, attributed by plaintiffs to a condition called non-arteritic anterior ischemic optic neuropathy, or NAION.&lt;/p&gt;
&lt;p&gt;According to reporting from AboutLawsuits.com, the potential link between NAION and semaglutide products such as Ozempic and Wegovy is expected to be a focus of early discovery in GLP-1 vision loss lawsuits. Legal reporting from JD Supra and The Legal Examiner has similarly described vision loss claims as an emerging area within the broader GLP-1 litigation, and Sokolove Law has published material on claims involving liraglutide products such as Saxenda.&lt;/p&gt;
&lt;p&gt;It is important to be precise about what this means. Discovery is a fact-gathering stage. Courts scheduling or prioritizing discovery on a scientific question have not decided that question. No court has determined that GLP-1 medications cause NAION, and the claims described below remain allegations that the manufacturers dispute.&lt;/p&gt;</content:encoded></item><item><title>June 2026 Depo-Provera Hearings and Case Timing</title><link>https://nulegal.com/blog/june-2026-depo-provera-hearings-and-case-timing/</link><guid isPermaLink="true">https://nulegal.com/blog/june-2026-depo-provera-hearings-and-case-timing/</guid><description>The June 2026 causation hearings in the Depo-Provera litigation could shape how quickly meningioma claims move forward. Here is what evidence rulings may change, what they may not, and how to prepare your case timeline.</description><pubDate>Wed, 29 Apr 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you are living with a meningioma diagnosis, waiting on a lawsuit timeline can feel overwhelming. The June 2026 causation hearings are important because they focus on whether key expert opinions are reliable enough for court. These hearings are often case-defining moments in mass torts. They do not decide every individual claim, but they can strongly influence what happens next. In plain terms, the court will evaluate scientific testimony about whether Depo-Provera can cause or contribute to meningioma in certain patients. That process can affect settlement leverage, bellwether preparation, and how aggressively cases move.&lt;/p&gt;
&lt;p&gt;A causation hearing usually addresses expert admissibility under Federal Rule of Evidence 702. The judge looks at methodology, data quality, and whether experts applied their methods reliably. This is different from deciding who should win your case. The legal question is often whether a jury is allowed to hear specific causation opinions. If opinions are admitted, plaintiffs generally gain momentum. If major opinions are limited or excluded, plaintiffs may need to adjust strategy or develop additional expert support. Either way, your case does not automatically disappear because one ruling is unfavorable.&lt;/p&gt;</content:encoded></item><item><title>2026 GLP-1 Vision Claims: NAION vs Diabetic Eye Disease</title><link>https://nulegal.com/blog/2026-glp-1-vision-claims-naion-vs-diabetic-eye-disease/</link><guid isPermaLink="true">https://nulegal.com/blog/2026-glp-1-vision-claims-naion-vs-diabetic-eye-disease/</guid><description>NAION and diabetic eye disease are not the same injury, and the distinction can materially affect a 2026 GLP-1 vision loss lawsuit. Learn which ophthalmology records, test results, and timeline details can strengthen an Ozempic or Wegovy claim.</description><pubDate>Wed, 22 Apr 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you developed sudden vision loss while using Ozempic or Wegovy, the diagnosis label in your chart can shape your legal claim. Many clients are told they have &amp;quot;diabetic eye disease&amp;quot; before a full neuro-ophthalmic workup is complete. That can happen because diabetes is common in GLP-1 users, and diabetic eye complications are familiar to clinicians. But non-arteritic anterior ischemic optic neuropathy (NAION) is a different condition with a different injury pattern. In litigation, that difference matters for both causation analysis and damages. This guide focuses on how to separate likely NAION from diabetic retinopathy or diabetic macular edema. For general case criteria, see our GLP-1 practice area. The goal is not self-diagnosis. The goal is to help you collect the right records early, before they are lost or overwritten.&lt;/p&gt;
&lt;p&gt;NAION is typically a sudden, painless drop in vision, often noticed on waking. Patients may describe a gray shadow, dimness, or a &amp;quot;missing&amp;quot; upper or lower field. The event is usually one eye at a time, though the fellow eye can be at future risk. Neuro-ophthalmology exams often document optic disc edema in the acute phase. Color vision changes and a relative afferent pupillary defect may also appear. Visual field testing may show altitudinal or arcuate defects rather than diffuse blur. NAION is an optic nerve ischemic event, not a retinal microvascular leak syndrome. Because medical evidence is still evolving, no single finding proves drug causation by itself. A careful differential diagnosis is what gives a claim credibility.&lt;/p&gt;</content:encoded></item><item><title>Telehealth Semaglutide and Lawsuit Eligibility: The Novo Nordisk-Hims Deal Explained</title><link>https://nulegal.com/blog/telehealth-semaglutide-and-lawsuit-eligibility-the-novo-nordisk-hims-deal-explai/</link><guid isPermaLink="true">https://nulegal.com/blog/telehealth-semaglutide-and-lawsuit-eligibility-the-novo-nordisk-hims-deal-explai/</guid><description>Learn how the Novo Nordisk and Hims &amp; Hers partnership affects compounded semaglutide users and potential GLP-1 injury lawsuit eligibility in 2026.</description><pubDate>Wed, 15 Apr 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;The telehealth GLP-1 market has exploded since 2022, with companies like Hims &amp;amp; Hers, Amazon Pharmacy, and others offering prescription semaglutide through online consultations. Many of these prescriptions are for compounded versions of semaglutide, custom-made formulations produced by pharmacy compounders rather than manufactured by Novo Nordisk (the maker of brand-name Ozempic and Wegovy).&lt;/p&gt;
&lt;p&gt;Now, a new partnership between Novo Nordisk and Hims &amp;amp; Hers is raising important questions: How will this deal change the landscape of GLP-1 prescribing? And most importantly for injured patients, could it affect your eligibility for the ongoing Ozempic/Wegovy lawsuit?&lt;/p&gt;
&lt;p&gt;Compounded semaglutide is not brand-name Ozempic or Wegovy. Instead, it&apos;s a custom-made version prepared by licensed pharmacy compounders using raw semaglutide powder. Compounders mix, package, and distribute these formulations directly to patients, often at lower costs and with faster shipping than traditional pharmacies.&lt;/p&gt;
&lt;p&gt;The FDA has raised concerns about compounded semaglutide in the past, particularly regarding quality control, sterility, and consistency. Unlike FDA-approved brand-name products, compounded drugs receive less regulatory oversight before reaching patients. This doesn&apos;t automatically mean they&apos;re unsafe, but it does mean patients may face additional risks if manufacturing standards vary.&lt;/p&gt;</content:encoded></item><item><title>What Depo-Provera&apos;s New Meningioma Warning Says, and When to See Your Doctor</title><link>https://nulegal.com/blog/depo-provera-users-need-to-know-what-the-fdas-new-label-warning-means-for-monito/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-users-need-to-know-what-the-fdas-new-label-warning-means-for-monito/</guid><description>What Depo-Provera&apos;s December 2025 label says about meningioma, the symptoms to watch for, and when women who used this contraceptive should talk to their doctor.</description><pubDate>Wed, 08 Apr 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you&apos;ve used Depo-Provera for contraception, the FDA&apos;s updated labeling about meningioma risk likely raises an important question: what should you do now? The warning itself is short: it tells prescribers what to watch for in patients on the drug, and it gives no screening or imaging advice. Understanding what this means, and what steps you should take, can help you stay informed about your health.&lt;/p&gt;
&lt;p&gt;In December 2025, the FDA added a warning about Depo-Provera and meningioma risk to the product&apos;s labeling. The label states that cases of meningioma have been reported following repeated administration of medroxyprogesterone acetate, the active ingredient in Depo-Provera, primarily with long-term use. It tells prescribers to monitor patients on Depo-Provera for signs and symptoms of meningioma, and to discontinue Depo-Provera if a meningioma is diagnosed. The patient information that comes with the drug describes a &amp;quot;possible increased risk for growth of a meningioma (a usually benign brain tumor), primarily when the product is used for a long time.&amp;quot;&lt;/p&gt;</content:encoded></item><item><title>Pancreatitis and GLP-1 Drugs: Symptoms, Diagnosis, and Legal Options</title><link>https://nulegal.com/blog/pancreatitis-and-glp-1-drugs-symptoms-diagnosis-and-legal-options/</link><guid isPermaLink="true">https://nulegal.com/blog/pancreatitis-and-glp-1-drugs-symptoms-diagnosis-and-legal-options/</guid><description>Learn how GLP-1 medications like Ozempic increase pancreatitis risk, recognize warning signs, and understand your legal options if you&apos;ve been harmed.</description><pubDate>Wed, 01 Apr 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Pancreatitis (inflammation of the pancreas) is a serious medical condition that has emerged as a significant concern among patients taking GLP-1 receptor agonists like Ozempic, Mounjaro, and Wegovy. These medications, originally approved for type 2 diabetes management and increasingly prescribed off-label for weight loss, have been linked to acute and chronic pancreatitis in recent clinical reports and case studies.&lt;/p&gt;
&lt;p&gt;The pancreas plays a critical role in digestion and blood sugar regulation. When it becomes inflamed, patients can experience severe pain, digestive complications, and even life-threatening complications like sepsis or organ failure. If you&apos;ve developed pancreatitis after starting a GLP-1 medication, understanding your symptoms, diagnosis pathway, and legal rights is essential.&lt;/p&gt;
&lt;p&gt;Acute pancreatitis typically develops suddenly and presents with distinctive warning signs:&lt;/p&gt;
&lt;p&gt;Chronic pancreatitis develops over time and may cause ongoing abdominal pain, malabsorption issues, and digestive difficulties. Some patients report that symptoms began or worsened within weeks of starting their GLP-1 medication, a temporal relationship that strengthens potential legal claims.&lt;/p&gt;</content:encoded></item><item><title>Depo-Provera and Meningioma: A Timeline of FDA Warnings and Studies</title><link>https://nulegal.com/blog/depo-provera-fda-timeline/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-fda-timeline/</guid><description>A chronological timeline of the Depo-Provera meningioma link, from early research through the BMJ study, FDA label update, and current litigation milestones.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;The connection between Depo-Provera and meningioma brain tumors did not emerge overnight. It developed over decades through a series of scientific studies, regulatory actions, and (critics argue) manufacturer inaction. This chronological timeline traces the key events from Depo-Provera&apos;s approval through the current litigation, documenting what was known, when it was known, and what Pfizer and the FDA did (or failed to do) in response.&lt;/p&gt;
&lt;p&gt;Understanding this timeline is critical for claimants, as it forms the factual backbone of the failure-to-warn claims at the heart of the Depo-Provera meningioma litigation.&lt;/p&gt;
&lt;p&gt;The FDA approved depot medroxyprogesterone acetate (DMPA), marketed as Depo-Provera, as an injectable contraceptive in October 1992. Manufactured by Upjohn (later acquired by Pfizer), Depo-Provera was administered as an intramuscular injection every three months.&lt;/p&gt;
&lt;p&gt;The approval came after decades of international use and a prolonged FDA review process that included concerns about cancer risk. Early studies had shown that DMPA caused breast tumors in beagle dogs, which delayed FDA approval for years. However, the approved labeling focused on breast cancer risk and did not include any warning about brain tumors or meningiomas.&lt;/p&gt;</content:encoded></item><item><title>The Depo-Provera MDL: Case Count, Timeline, and What to Expect</title><link>https://nulegal.com/blog/depo-provera-mdl-tracker/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-mdl-tracker/</guid><description>Track the Depo-Provera meningioma MDL: current case count, court proceedings, bellwether selection, Rule 702 hearings, and the December 2026 pilot trial timeline.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;The Depo-Provera meningioma litigation is one of the most significant pharmaceutical mass tort cases currently moving through the federal court system. With more than 3,000 lawsuits filed and key pretrial milestones approaching, understanding where the case stands, and what comes next, is essential for current and prospective claimants. This tracker provides an overview of the MDL&apos;s current status and upcoming events.&lt;/p&gt;
&lt;p&gt;The Depo-Provera meningioma cases have been consolidated into a multidistrict litigation (MDL) for coordinated pretrial proceedings. The consolidation was ordered by the Judicial Panel on Multidistrict Litigation (JPML), which determined that centralizing the cases would promote efficient handling of common discovery and pretrial issues.&lt;/p&gt;
&lt;p&gt;Key facts at a glance:&lt;/p&gt;
&lt;p&gt;Following the publication of the BMJ study and growing awareness of the Depo-Provera/meningioma link, lawsuits began filing in federal courts across the country. The JPML consolidated these cases into the MDL to prevent duplicative discovery and inconsistent pretrial rulings.&lt;/p&gt;</content:encoded></item><item><title>Depo-Provera Pilot Trial December 2026: What It Means for Your Case</title><link>https://nulegal.com/blog/depo-provera-pilot-trial-2026/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-pilot-trial-2026/</guid><description>The first Depo-Provera meningioma pilot trial is set for December 2026. Learn what bellwether trials are, what&apos;s being argued, potential outcomes, and the impact on settlement.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;The Depo-Provera meningioma litigation is approaching one of its most significant milestones: the first pilot trial, currently targeted for December 2026. This trial will be the first time a Depo-Provera meningioma case is presented to a jury, and its outcome will have far-reaching implications for the more than 3,000 cases pending in the multidistrict litigation. Understanding what a pilot trial is, what will be argued, and how it affects your case is essential for every current and prospective claimant.&lt;/p&gt;
&lt;p&gt;A pilot trial (also called a bellwether trial) is a test case selected from the larger pool of cases in an MDL to go to trial first. The purpose is to provide both sides, plaintiffs and the defendant (Pfizer), with real-world data about how juries respond to the evidence.&lt;/p&gt;
&lt;p&gt;Pilot trials serve several critical functions:&lt;/p&gt;
&lt;p&gt;The pilot trial outcome is not technically binding on other cases in the MDL. However, its practical impact is enormous. A plaintiff verdict signals to Pfizer that it faces significant exposure across thousands of cases. A defense verdict may slow settlement momentum but does not end the litigation.&lt;/p&gt;</content:encoded></item><item><title>Depo-Provera Meningioma Settlements: What Comparable Cases Tell Us</title><link>https://nulegal.com/blog/depo-provera-settlements/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-settlements/</guid><description>What can comparable pharmaceutical mass tort settlements tell us about potential Depo-Provera meningioma case values? Analysis of factors affecting compensation and timeline expectations.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Women diagnosed with meningioma brain tumors after using Depo-Provera are understandably asking: what might my case be worth? While no attorney can ethically guarantee a specific dollar amount before a case resolves (and anyone who does should be viewed with skepticism), we can look at comparable pharmaceutical mass tort settlements to understand the range of factors that influence compensation and what the litigation timeline may look like.&lt;/p&gt;
&lt;p&gt;The Depo-Provera meningioma litigation is still in its early stages, with bellwether trials not yet concluded. However, the history of similar pharmaceutical cases provides a meaningful framework for understanding potential outcomes.&lt;/p&gt;
&lt;p&gt;In mass tort litigation, settlements typically follow a structured process. After bellwether trials establish the strength of plaintiff claims, defendants often propose a global settlement program, a fund that compensates claimants based on the severity of their individual injuries. Unlike class actions where everyone receives the same amount, mass tort settlements use a tiered system that accounts for individual differences.&lt;/p&gt;</content:encoded></item><item><title>Depo-Provera vs. Ozempic Lawsuit: Key Differences Explained</title><link>https://nulegal.com/blog/depo-provera-vs-ozempic-lawsuit/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-vs-ozempic-lawsuit/</guid><description>Compare the Depo-Provera meningioma lawsuit and the GLP-1/Ozempic lawsuit side by side: drug type, injuries, MDL status, case counts, and settlement timelines.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;The Depo-Provera meningioma lawsuit and the GLP-1/Ozempic lawsuit are two of the largest pharmaceutical litigations in the United States. Both involve widely prescribed medications linked to serious injuries that manufacturers allegedly failed to warn about, but the drugs, injuries, and litigation timelines differ significantly.&lt;/p&gt;
&lt;p&gt;These two litigations involve fundamentally different categories of medication. Depo-Provera is an injectable hormonal contraceptive containing medroxyprogesterone acetate, a synthetic progestin administered every three months. It has been on the U.S. market since 1992 and has been used by millions of women for birth control. The GLP-1 receptor agonists (including Ozempic, Wegovy, Mounjaro, Trulicity, Saxenda, and Rybelsus) are a newer class of drugs originally developed for type 2 diabetes and increasingly prescribed for weight management. These medications work by mimicking the incretin hormone GLP-1 to regulate blood sugar and appetite.&lt;/p&gt;
&lt;p&gt;The injuries at the center of each lawsuit are dramatically different. In the Depo-Provera litigation, plaintiffs allege that prolonged use of the contraceptive caused meningiomas, typically benign but potentially debilitating brain tumors that can require surgery, cause neurological symptoms, and in some cases prove life-threatening. A 2024 BMJ study found that prolonged Depo-Provera use was associated with a significantly elevated meningioma risk. In the GLP-1 litigation, the injuries are primarily gastrointestinal: gastroparesis, bowel obstruction, gallbladder disease, pancreatitis, and NAION (vision loss).&lt;/p&gt;</content:encoded></item><item><title>Can I File a Depo-Provera Lawsuit if I Used It Years Ago?</title><link>https://nulegal.com/blog/depo-provera-years-ago/</link><guid isPermaLink="true">https://nulegal.com/blog/depo-provera-years-ago/</guid><description>Wondering if you can still file a Depo-Provera meningioma lawsuit if you used the drug years or decades ago? Learn how the discovery rule and statutes of limitations work.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;One of the most common questions from women who developed meningiomas is: &amp;quot;I used Depo-Provera years ago. Is it too late to file a lawsuit?&amp;quot; The short answer for many women is no, it is not too late. The legal rules governing filing deadlines are more nuanced than most people realize, and the unique circumstances of the Depo-Provera litigation, particularly the fact that the risk was not publicly acknowledged until recently, work in favor of claimants who used the drug in the past.&lt;/p&gt;
&lt;p&gt;Understanding how statutes of limitations, the discovery rule, and tolling provisions apply to your situation is essential for protecting your legal rights.&lt;/p&gt;
&lt;p&gt;A statute of limitations is a law that sets the maximum time period within which a lawsuit must be filed after an event occurs. In personal injury cases, including pharmaceutical injury claims, the statute of limitations varies by state but typically ranges from one to six years.&lt;/p&gt;
&lt;p&gt;If you miss the statute of limitations deadline, your claim is generally barred, meaning you lose the right to pursue compensation, regardless of how strong your case may otherwise be. This is why understanding when your particular deadline starts, and whether any exceptions apply, is so important.&lt;/p&gt;</content:encoded></item><item><title>Which GLP-1 Drugs Are Included in the Ozempic Lawsuit?</title><link>https://nulegal.com/blog/do-you-qualify-glp1-lawsuit/</link><guid isPermaLink="true">https://nulegal.com/blog/do-you-qualify-glp1-lawsuit/</guid><description>Find out which GLP-1 receptor agonist drugs are covered in the Ozempic lawsuit, what injuries qualify, and how the MDL process works for affected patients.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;The GLP-1 receptor agonist litigation (commonly referred to as the &amp;quot;Ozempic lawsuit&amp;quot;) covers far more than a single drug. Multiple GLP-1 medications manufactured by Novo Nordisk, Eli Lilly, and other pharmaceutical companies are included in the federal multidistrict litigation (MDL 3094), and a range of serious injuries may qualify for legal claims. If you took any GLP-1 drug and experienced severe side effects, understanding which medications and injuries are covered is the essential first step.&lt;/p&gt;
&lt;p&gt;The following GLP-1 receptor agonists are currently included in or related to the MDL:&lt;/p&gt;
&lt;p&gt;Manufactured by Novo Nordisk, Ozempic is prescribed for type 2 diabetes management. It is the most widely recognized drug in the litigation and the one that brought national attention to the risks of GLP-1 receptor agonists. Ozempic is administered as a weekly injection.&lt;/p&gt;
&lt;p&gt;Also manufactured by Novo Nordisk, Wegovy contains the same active ingredient as Ozempic, semaglutide, but is specifically approved for chronic weight management. Because it uses the same compound, Wegovy carries the same risk profile for gastrointestinal and other injuries.&lt;/p&gt;</content:encoded></item><item><title>Gastric Emptying Study: Why It Matters for Your Ozempic Claim</title><link>https://nulegal.com/blog/gastric-emptying-study-ozempic/</link><guid isPermaLink="true">https://nulegal.com/blog/gastric-emptying-study-ozempic/</guid><description>Learn what a gastric emptying study (GES) is, how it&apos;s performed, and why the court overseeing the federal GLP-1 lawsuits requires one for an Ozempic gastroparesis claim.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you developed gastroparesis after taking Ozempic, Wegovy, Mounjaro, or another GLP-1 receptor agonist, the court overseeing the federal GLP-1 litigation requires a diagnosis based on a properly performed gastric emptying study: scintigraphy, a breath test, or a wireless motility capsule (Document 468). A diagnosis made from symptoms alone does not meet that standard.&lt;/p&gt;
&lt;p&gt;Understanding what a gastric emptying study is, how it works, and what results you need is essential for anyone considering or pursuing a legal claim.&lt;/p&gt;
&lt;p&gt;A gastric emptying study measures how fast your stomach empties. The court accepts three kinds: scintigraphy, which its memorandum calls the &amp;quot;gold standard&amp;quot;, a breath test and a wireless motility capsule, all described by the National Institute of Diabetes and Digestive and Kidney Diseases. This guide walks through scintigraphy, a nuclear medicine test that measures how quickly food moves from your stomach into your small intestine.&lt;/p&gt;
&lt;p&gt;The test directly measures your gastric motility, the ability of your stomach muscles to contract and push food through your digestive system. When GLP-1 drugs cause gastroparesis, they slow or paralyze these contractions, and the gastric emptying study captures this impairment in objective, measurable data.&lt;/p&gt;</content:encoded></item><item><title>Mounjaro, Wegovy, Trulicity: GLP-1 Lawsuits Beyond Ozempic</title><link>https://nulegal.com/blog/glp1-drugs-beyond-ozempic/</link><guid isPermaLink="true">https://nulegal.com/blog/glp1-drugs-beyond-ozempic/</guid><description>The GLP-1 litigation extends well beyond Ozempic. Learn about lawsuits involving Mounjaro, Wegovy, Trulicity, Saxenda, and Rybelsus, including injury profiles and litigation status.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;When people hear &amp;quot;Ozempic lawsuit,&amp;quot; they often assume the litigation is limited to a single drug. In reality, the GLP-1 receptor agonist litigation, consolidated in MDL 3094, encompasses an entire class of medications manufactured by multiple pharmaceutical companies. If you took Mounjaro, Wegovy, Trulicity, Saxenda, or Rybelsus and suffered serious side effects, your legal options may be identical to those of Ozempic users.&lt;/p&gt;
&lt;p&gt;Here is what you need to know about each drug, its manufacturer, the injuries associated with it, and the current state of litigation.&lt;/p&gt;
&lt;p&gt;Mounjaro is manufactured by Eli Lilly and Company and was approved by the FDA in 2022 for type 2 diabetes. It contains tirzepatide, a dual GIP/GLP-1 receptor agonist, meaning it activates two different incretin receptors rather than just one. In 2023, it was also approved under the brand name Zepbound for chronic weight management.&lt;/p&gt;
&lt;p&gt;While Ozempic targets only the GLP-1 receptor, Mounjaro targets both GLP-1 and GIP receptors. This dual mechanism has produced impressive results for blood sugar control and weight loss in clinical trials, but it also means the drug has a potent effect on gastric emptying, the same mechanism that drives gastroparesis risk.&lt;/p&gt;</content:encoded></item><item><title>GLP-1 Medications Compared: Ozempic vs. Wegovy vs. Mounjaro vs. Trulicity</title><link>https://nulegal.com/blog/glp1-medications-compared/</link><guid isPermaLink="true">https://nulegal.com/blog/glp1-medications-compared/</guid><description>A side-by-side comparison of GLP-1 medications involved in the mass tort litigation (Ozempic, Wegovy, Mounjaro, Trulicity, Saxenda, and Rybelsus), including active ingredients, manufacturers, and lawsuit status.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Six GLP-1 receptor agonist medications are at the center of the mass tort litigation consolidated in MDL 3094. While all six drugs share a similar mechanism of action (mimicking the incretin hormone GLP-1 to regulate blood sugar and appetite), they differ in active ingredient, manufacturer, approved uses, and administration method. All six are included in the current litigation.&lt;/p&gt;
&lt;p&gt;Ozempic is the most widely recognized drug in the GLP-1 litigation. Approved by the FDA in 2017 for type 2 diabetes, it contains semaglutide and is administered as a weekly subcutaneous injection. Ozempic became a cultural phenomenon due to widespread off-label use for weight loss, which dramatically expanded its user base beyond the diabetic population. The injuries most commonly alleged in Ozempic claims include gastroparesis, bowel obstruction, gallbladder disease, and pancreatitis. A 2023 JAMA study found elevated rates of gastrointestinal adverse events among semaglutide users compared to other diabetes and weight-loss medications.&lt;/p&gt;</content:encoded></item><item><title>How Mass Tort Lawsuits Work: A Plain-English Guide</title><link>https://nulegal.com/blog/how-mass-tort-lawsuits-work/</link><guid isPermaLink="true">https://nulegal.com/blog/how-mass-tort-lawsuits-work/</guid><description>A clear, jargon-free guide to mass tort lawsuits: how MDLs differ from class actions, what bellwether trials are, how settlements work, and what clients should expect.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you are considering filing a claim in a pharmaceutical mass tort (whether involving Depo-Provera, Ozempic and GLP-1 drugs, or another product), understanding how the legal process works can reduce anxiety and help you make informed decisions. Mass tort lawsuits are complex, but the core concepts are straightforward. This guide explains the process in plain English.&lt;/p&gt;
&lt;p&gt;A mass tort is a type of litigation in which many individuals file separate lawsuits against the same defendant (or defendants) for injuries caused by the same product, drug, or action. Unlike a single personal injury case, a mass tort involves hundreds or thousands of plaintiffs, but each person&apos;s case is treated individually.&lt;/p&gt;
&lt;p&gt;The term &amp;quot;tort&amp;quot; simply means a civil wrong that causes harm. In pharmaceutical mass torts, the &amp;quot;wrong&amp;quot; is typically the manufacturer&apos;s failure to adequately warn patients and doctors about known risks of a drug.&lt;/p&gt;
&lt;p&gt;People often confuse mass torts with class actions. They are fundamentally different:&lt;/p&gt;</content:encoded></item><item><title>Ozempic and Bowel Obstruction: Symptoms, Risks, and Legal Options</title><link>https://nulegal.com/blog/ozempic-bowel-obstruction/</link><guid isPermaLink="true">https://nulegal.com/blog/ozempic-bowel-obstruction/</guid><description>Bowel obstruction is a serious, potentially life-threatening side effect of GLP-1 drugs like Ozempic. Learn about symptoms, emergency risks, and legal claims for affected patients.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Bowel obstruction (also called intestinal obstruction) is one of the most dangerous injuries associated with GLP-1 receptor agonist drugs like Ozempic, Wegovy, and Mounjaro. Unlike gastroparesis, which involves slowed stomach emptying, bowel obstruction involves a physical blockage of the intestines that can become a life-threatening medical emergency requiring hospitalization and surgery. If you developed a bowel obstruction after taking a GLP-1 drug, understanding the medical and legal landscape is critical.&lt;/p&gt;
&lt;p&gt;A bowel obstruction occurs when the normal passage of food, fluids, and digestive contents through the intestines is blocked. The blockage can be partial (some material passes through) or complete (nothing passes through). Complete bowel obstructions are medical emergencies that require immediate treatment.&lt;/p&gt;
&lt;p&gt;The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) categorizes intestinal obstructions based on their cause and location:&lt;/p&gt;
&lt;p&gt;Bowel obstruction symptoms typically develop rapidly and can escalate to emergency status within hours:&lt;/p&gt;</content:encoded></item><item><title>Ozempic Gallbladder Disease: Qualifying Injuries in the GLP-1 MDL</title><link>https://nulegal.com/blog/ozempic-gallbladder-disease/</link><guid isPermaLink="true">https://nulegal.com/blog/ozempic-gallbladder-disease/</guid><description>Gallstones, cholecystitis, and cholecystectomy after taking Ozempic or other GLP-1 drugs: learn about qualifying gallbladder injuries, FDA warnings, and your legal options.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Gallbladder disease is one of the most common serious injuries linked to GLP-1 receptor agonist drugs, and it is a qualifying injury in the GLP-1 multidistrict litigation. Thousands of patients who took Ozempic, Wegovy, Mounjaro, or other GLP-1 drugs have developed gallstones, cholecystitis (gallbladder inflammation), or required cholecystectomy (surgical removal of the gallbladder). The FDA has acknowledged the risk in its own labeling requirements, and the evidence connecting GLP-1 drugs to gallbladder disease continues to grow.&lt;/p&gt;
&lt;p&gt;The connection between GLP-1 drugs and gallbladder disease is driven by two related mechanisms:&lt;/p&gt;
&lt;p&gt;GLP-1 receptor agonists can cause significant, rapid weight loss, often 15-20% of body weight over months. Rapid weight loss is a well-established risk factor for gallstone formation. When the body loses weight quickly, the liver secretes excess cholesterol into bile, and the gallbladder does not empty as efficiently. This creates conditions for cholesterol to crystallize into gallstones.&lt;/p&gt;</content:encoded></item><item><title>Ozempic and Vision Loss (NAION): The Emerging Legal Claims</title><link>https://nulegal.com/blog/ozempic-naion-vision-loss/</link><guid isPermaLink="true">https://nulegal.com/blog/ozempic-naion-vision-loss/</guid><description>A Harvard study links GLP-1 drugs like Ozempic to NAION, a serious form of sudden vision loss. Learn about the condition, the research, and your legal options.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;An emerging and deeply concerning injury linked to GLP-1 receptor agonist drugs is non-arteritic anterior ischemic optic neuropathy (NAION), a condition that causes sudden, painless vision loss that is often permanent. A 2024 study from Harvard Medical School published in JAMA Ophthalmology found that patients using semaglutide (the active ingredient in Ozempic and Wegovy) had a significantly elevated risk of developing NAION compared to non-users. This research has opened a new front in the GLP-1 litigation and raised urgent questions for the millions of patients taking these medications.&lt;/p&gt;
&lt;p&gt;NAION occurs when blood flow to the optic nerve (the nerve that transmits visual information from the eye to the brain) is suddenly reduced or interrupted. This lack of blood flow damages the nerve fibers, resulting in vision loss that typically affects one eye at a time.&lt;/p&gt;
&lt;p&gt;According to the National Eye Institute (NEI), key characteristics of NAION include:&lt;/p&gt;
&lt;p&gt;NAION is the most common cause of sudden optic nerve-related vision loss in adults over 50, but the Harvard study&apos;s findings suggest that GLP-1 drugs may be causing it in younger patients and at significantly higher rates than background population rates.&lt;/p&gt;</content:encoded></item><item><title>Already Diagnosed? How to Start Your Mass Tort Claim</title><link>https://nulegal.com/blog/start-your-mass-tort-claim/</link><guid isPermaLink="true">https://nulegal.com/blog/start-your-mass-tort-claim/</guid><description>A step-by-step guide to filing a mass tort claim after a diagnosis, from gathering documents to filing your case. Covers GLP-1 drug claims, and Depo-Provera meningioma claims, which NuLegal no longer reviews.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you have been diagnosed with a serious injury linked to a pharmaceutical product (whether a meningioma after Depo-Provera or gastroparesis after a GLP-1 drug), you may be wondering how to actually start the legal process. Filing a mass tort claim can feel overwhelming, especially when you are also managing a medical condition. This guide walks you through every step, from diagnosis to filing, so you know exactly what to expect and what to do.&lt;/p&gt;
&lt;p&gt;Before pursuing a legal claim, you need a confirmed medical diagnosis of a qualifying injury. In mass tort litigation, the strength of your case depends heavily on the quality of your medical documentation.&lt;/p&gt;
&lt;p&gt;NuLegal no longer reviews these claims; this is what a lawyer who handles them will usually ask for.&lt;/p&gt;
&lt;p&gt;If you suspect you have a qualifying injury but have not been formally diagnosed, see your doctor first. A confirmed diagnosis is the foundation of any viable claim.&lt;/p&gt;
&lt;p&gt;Once your diagnosis is confirmed, the next step is collecting the medical records that document both your drug exposure and your injury. You will need:&lt;/p&gt;</content:encoded></item><item><title>What Is a Meningioma? Understanding the Brain Tumor Linked to Depo-Provera</title><link>https://nulegal.com/blog/what-is-meningioma/</link><guid isPermaLink="true">https://nulegal.com/blog/what-is-meningioma/</guid><description>A comprehensive medical explainer on meningioma brain tumors: types, symptoms, diagnosis, treatment options, and the established link to Depo-Provera contraceptive injections.</description><pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;A meningioma is a tumor that develops in the meninges, the three layers of protective tissue that surround the brain and spinal cord. Meningiomas are the most common type of primary brain tumor, accounting for approximately 40% of all brain tumors diagnosed in the United States. While they are typically classified as benign (non-cancerous), this classification can be misleading: meningiomas can grow large enough to compress brain tissue, causing serious neurological symptoms that dramatically impact quality of life.&lt;/p&gt;
&lt;p&gt;For women who used Depo-Provera contraceptive injections, understanding meningiomas is critical. A growing body of scientific research has established a link between long-term use of depot medroxyprogesterone acetate (DMPA) and an increased risk of developing these brain tumors. The FDA&apos;s December 2025 label update now warns that cases of meningioma have been reported following repeated use, primarily with long-term use.&lt;/p&gt;
&lt;p&gt;Meningiomas are classified by the World Health Organization (WHO) into three grades based on their cellular characteristics and behavior:&lt;/p&gt;</content:encoded></item><item><title>Do You Qualify for the Depo-Provera Meningioma Lawsuit?</title><link>https://nulegal.com/blog/do-you-qualify-depo-provera-lawsuit/</link><guid isPermaLink="true">https://nulegal.com/blog/do-you-qualify-depo-provera-lawsuit/</guid><description>What a Depo-Provera meningioma claim generally requires and the records involved, kept as information: NuLegal no longer reviews these claims.</description><pubDate>Wed, 25 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;If you used Depo-Provera and were later diagnosed with a meningioma, you may be wondering whether you qualify to file a legal claim. The Depo-Provera meningioma litigation has grown rapidly, with thousands of women pursuing claims against Pfizer for failing to warn about the link between their injectable contraceptive and brain tumors. This guide breaks down the key eligibility criteria so you can determine whether your situation qualifies.&lt;/p&gt;
&lt;p&gt;The qualification requirements for a Depo-Provera meningioma claim are straightforward. To be eligible, you generally need to meet three conditions:&lt;/p&gt;
&lt;p&gt;You must have received at least one injection of Depo-Provera (depot medroxyprogesterone acetate, or DMPA) or Depo-SubQ Provera 104. This includes the standard intramuscular injection and the subcutaneous formulation.&lt;/p&gt;
&lt;p&gt;Cases tend to be strongest when the patient received multiple injections over an extended period, typically a year or more of use. However, even shorter-term use may qualify depending on the circumstances of your diagnosis. Your medical records or pharmacy records should document your injection history.&lt;/p&gt;</content:encoded></item><item><title>FDA Warns of Meningioma Brain Tumors After Long-Term Depo-Provera Use</title><link>https://nulegal.com/blog/fda-warns-depo-provera-meningioma/</link><guid isPermaLink="true">https://nulegal.com/blog/fda-warns-depo-provera-meningioma/</guid><description>In December 2025, the FDA approved a warning on Depo-Provera&apos;s label that meningioma brain tumors have been reported after repeated, mostly long-term use. Learn what this means for your legal rights.</description><pubDate>Wed, 25 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;In December 2025, the U.S. Food and Drug Administration took a significant step by adding a new warning to the prescribing label for Depo-Provera and Depo-SubQ Provera 104, the widely used injectable contraceptives manufactured by Pfizer. The updated label now warns that cases of meningioma have been reported following repeated use of depot medroxyprogesterone acetate (DMPA), primarily with long-term use. A meningioma is a type of brain tumor that, while typically classified as benign, can cause serious and life-altering symptoms.&lt;/p&gt;
&lt;p&gt;This label change came after years of mounting scientific evidence and growing pressure from patient advocacy groups. For the millions of women who have used Depo-Provera, the FDA&apos;s acknowledgment raises urgent questions about health risks, medical monitoring, and legal rights.&lt;/p&gt;
&lt;p&gt;A meningioma is a tumor that forms in the meninges, the protective membranes that surround the brain and spinal cord. Although most meningiomas are classified as non-cancerous, that label can be misleading. These tumors can grow large enough to compress brain tissue, causing debilitating symptoms including:&lt;/p&gt;</content:encoded></item><item><title>Gastroparesis After Ozempic: Symptoms, Diagnosis, and Legal Options</title><link>https://nulegal.com/blog/gastroparesis-after-ozempic/</link><guid isPermaLink="true">https://nulegal.com/blog/gastroparesis-after-ozempic/</guid><description>If you developed gastroparesis or other serious stomach problems after taking Ozempic, Wegovy, or Mounjaro, you may have legal options. Here&apos;s what you need to know.</description><pubDate>Wed, 25 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;Gastroparesis, sometimes called stomach paralysis, has become one of the most serious injuries at the center of the GLP-1 receptor agonist litigation. Thousands of patients who took Ozempic, Wegovy, Mounjaro, or other GLP-1 drugs for diabetes management or weight loss have reported developing severe gastroparesis, a condition that can dramatically affect quality of life and, in some cases, require hospitalization or surgery. If you are dealing with gastroparesis after taking one of these medications, this guide covers what you need to know about the condition, the legal landscape, and your options.&lt;/p&gt;
&lt;p&gt;Gastroparesis is a condition in which the stomach loses its ability to empty food at a normal rate. In a healthy digestive system, the stomach contracts to push food into the small intestine for further digestion. When gastroparesis occurs, these contractions slow down or stop working properly, causing food to remain in the stomach for abnormally long periods.&lt;/p&gt;
&lt;p&gt;The consequences can be severe and debilitating:&lt;/p&gt;</content:encoded></item><item><title>Ozempic Lawsuit Update: What You Need to Know in 2026</title><link>https://nulegal.com/blog/ozempic-lawsuit-2026-update/</link><guid isPermaLink="true">https://nulegal.com/blog/ozempic-lawsuit-2026-update/</guid><description>Where the Ozempic, Wegovy and Mounjaro lawsuits (MDL 3094) stand in 2026: the judge, the gastric emptying study requirement, and why no bellwether trial is set.</description><pubDate>Wed, 25 Mar 2026 00:00:00 GMT</pubDate><content:encoded>&lt;p&gt;The litigation against the manufacturers of GLP-1 receptor agonist drugs, including Ozempic, Wegovy, Rybelsus (Novo Nordisk), and Mounjaro (Eli Lilly), is consolidated in one federal court in Pennsylvania. More than 2,600 cases were in the multidistrict litigation (MDL 3094) when the court ruled in August 2025 (Document 465), and our case page carries the current count from the Judicial Panel on Multidistrict Litigation. If you or someone you know has experienced serious side effects from these medications, here is where things stand and what you should know.&lt;/p&gt;
&lt;p&gt;The GLP-1 lawsuits have been consolidated in the U.S. District Court for the Eastern District of Pennsylvania under MDL No. 3094, before Judge Karen Spencer Marston. This consolidation allows the court to manage pretrial proceedings (including discovery, expert testimony, and key legal motions) efficiently across thousands of individual cases.&lt;/p&gt;
&lt;p&gt;The MDL has not reached bellwether trials. In Case Management Order No. 18 the court took up two cross-cutting questions first, how gastroparesis is diagnosed and preemption with the adequacy of the warnings, and held a third, general causation, for more briefing; Case Management Order No. 32 now schedules the second and third together. The court decided the first in August 2025, and closing arguments on the expert challenges for the other two were set for October 13, 2026 (order of October 8, 2026); we cover the August 2025 ruling and what is still pending in what the gastric emptying study ruling means. Bellwether cases are a small group of representative lawsuits selected from the larger pool. They are tried individually and serve as test cases that help both sides evaluate the strength of the evidence, the range of potential outcomes, and the viability of broader resolution.&lt;/p&gt;</content:encoded></item></channel></rss>